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 This thesis reports the crystallization of two new quasiracemates, the synthesis of 
a new oxadiazinanone and the identification of crystals of two new compounds. In 
previous research the quasiracemates, (5R,6S )-4-cyclohexyl-5-methyl-6-phenyl-2H-
1,3,4-oxadiazinan-2-one and (5S,6R)-4-isopropyl-5-methyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one, were mixed in solution and crystallized.  Instead of fractionally 
crystallizing, as would be expected, the compounds formed quasiracemic co-crystals. 
This suggested that other mixtures of oxadiazinanones would be possible candidates for 
studying compounds which fail to fractionally crystallize.  
 The first step in the process involves the synthesis of oxadiazinanones, using 
literature methods.  A 4-step process is employed involving alkylation, nitrosation, 
reduction and cyclization. Because the starting material, norephedrine, is a chiral 
molecule, the desired enantiomer is synthesized starting with the proper enantiomer of 
norephedrine—either the (1S,2R) or 1(R,2S) enantiomers.  A new oxadiazinanone, 
(5R,6S)-4-cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one, was synthesized. 
After synthesis, the oxadiazinanones are mixed together and crystallized using vapor 
diffusion. X-ray diffraction is used to study the structures to determine the presence of 
quasiracemates. 
 From the sixteen racemic pairs compared, it was found that quasiracemates were 
formed from oxadiazinanones containing either an N4-cyclopentyl substituent or an N4-
cyclohexyl substituent. The quasiracemate formed has a lower Z’ than at least one of the 
quasienantiomers in the structure.  
 Two additional compounds were synthesized, and the crystal structures were 
identified . These crystals were obtained when the intended N4-ethylated and N4-n-
butylated oxadiazinanones failed to cyclize in the final step of the oxadiazinanone 
synthesis. 
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CHAPTER I 
 
OXADIAZINANONE RESEARCH-HOW AND WHY? 
 
Fractional Crystallization 
 Typically, when different compounds are mixed together and crystallized, the 
components of the mixture crystallize as pure compounds. This happens at different times 
based on the solubility of each of the compounds. This process, called fractional 
crystallization, is used as a separation technique in industrial applications.  In a solution, 
the desired product is usually present in a greater concentration than the impurities and, 
generally, is deposited first. The impurities are left in solution. The failure to fractionally 
crystallize occurs when one of the compounds co-crystallizes with another compound 
also present in the solution. This results in a new crystalline product which is a 
combination of the original compounds.1  
 Several conditions seem to increase the likelihood of co-crystallization. 
When enantiomers crystallize they almost always co-crystalize as the corresponding 
racemate. This is due to the presence of symmetry elements, such as inversion or glide 
planes, which are very favorable to crystal-packing as well as the fact that both 
enantiomers have identical physical properties, including solubility. In fact, the 
occurrence of fractional crystallization of enantiomers is so rare it is given a special 
name, spontaneous resolution. When a crystal has inversion or glide planes as symmetry 
elements, the crystal is able to pack more densely which decreases the size of the crystal. 
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This decrease in size and increase in density is favorable to crystal. packing.2 
Quasiracemates, as defined by the International, Union of Pure and Applied Chemistry 
(IUPAC),  are crystals composed of a 1:1 ratio of  “almost enantiomers.”3 Husebye, in the 
1960s, reported that quasiracemates generally have structures with a great deal of 
similarity to the corresponding racemates. This observation may provide some support to 
the importance of inversion symmetry in co-crystallization.1, 4 Quasiracemates, because 
they have pseudo inversion centers, may be able to pack in a smaller volume, thus 
reducing the size of the asymmetric unit in the same manner as the co-crystallization 
observed in racemates.  
In addition to strong inversion symmetry, hydrogen-bonding contributes to co-
crystallization.2 Hydrogen bonds are somewhat elastic and this elasticity allows the 
distances and angles to vary at a small cost in energy which simplifies the bonding in a 
co-crystal. Therefore, there are a large number of co-crystals with either a carboxylic 
group or an amide group.1  
Often, however, it is difficult to determine the reason for co-crystallization. 
Kelley et al, created a list of quasiracemic crystals.1 The definition the researchers 
employed stated that quasiracemic crystals are co-crystals formed by molecules which 
are almost enantiomers but differ by the substitution of a few atoms. Of particular note is 
that the researchers found the formation of quasiracemic crystals is rare. In 2011 there 
were over 400,000 structures in the Cambridge Structural Database. Of these, only 114 
quasiracemates were identified as quasiracemates.1  
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A Brief History of Quasienantiomer Research 
Louis Pasteur’s earliest chemical studies were in the field of crystallography. In 
1846, he found that tartaric acid had optical activity, but paratartaric acid had none 
leading him to believe there were two kinds of crystals present although most other 
chemical properties were the same in the two compounds. He noticed that the edges of 
the crystals were asymmetrical—the surfaces on some of them were facing right and 
some, left. Using a dissecting needle and a microscope, he separated the crystals into two 
piles based on these differences. He recognized the difference in optical activity, 
extended his observations to the molecular level and realized that the two kinds of 
crystals were mirror images. He wrote his doctoral dissertation on this subject in 1847.5, 6  
The basis for chirality and stereoisomerism was laid by van’t Hoff and Le Bel in 
1874 when, independently, they each proposed the existence of tetrahedral carbon with a 
tetrahedral valence. In consequence of this, the idea of enantiomerism came into being. 
Enantiomers are compounds with the same chemical constitution which are mirror-
images of each other, but are non-superimposable.7 William Thomson, (Lord Kelvin), 
first introduced this definition in 1883 at a lecture given to the Oxford University Junior 
Scientific Club.8 It was not reintroduced into stereochemical literature until 1965 by 
Mislow9 and 1966  Cahn, Ingold and Prelog.5  
In 1899, Centnerswer studied a 1:1 mixture of (-)-bromosuccinic acid (Figure 1.1 
left) and (+)-chlorosuccinic acid Figure 1.1  right).7, 10 He found that this mixture had 
phase properties similar to those of the corresponding true racemic compounds for each 
of the molecules. The mixture contained neither isomers nor enantiomers, but had an 
“almost” or “pseudo” mirror-image relationship.7, 10  
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H
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Figure 1.1  Comparison of (left) chlorosuccinic acid and (right) bromosuccinic acid. 
 
 Most of the studies of quasiracemates, and the reasons for their formation, were 
conducted in the 1960s and 1970s by A. Fredga.11 Fredga, in 1960, first used the term 
“quasi-racemate” to distinguish this class of compounds.12 This research used melting 
point phase diagrams and found that these sufficed to determine true racemic compounds, 
racemic conglomerates, as well as quasiracemates. A racemic conglomerate is a mixture 
of two types of crystals where each crystal is composed of only one enantiomer, but the 
entire mixture has an equimolar amount of both enantiomers.3 This study provided clear 
evidence for the presence of quasiracemates, identified necessary criteria for the selection 
of sterically similar molecules, and used the molecular topology to design new 
quasiracemates.11  
In 1966, Jerome and Isabella Karle determined the structure of the 
quasiracemates, (R)-2-(3-bromophenoxy) propionic acid and (S)-2-(3-methoxyphenoxy) 
propionic acid (Figure 1.2).13 Their study of the  pseudo inversion symmetry of this 
quasiracemate proved to be one of the first investigations into packing motifs in 
quasiracemates. The relationship of inversion packing to packing motif is now firmly 
established.12  
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CO2H
(S)
OH3CO
HO2C
(R) O Br  
Figure 1.2  The quasiracemate of (R)-2-(3-bromophenoxy)propionic acid (right) and (S)-
2-(3-methoxyphenoxy)propionic acid (left). 
 
 
In the 1990’s the late Margaret Etter, a pioneer in crystal engineering, studied 
hydrogen bonding motifs in crystals. The research gave insight into the role of hydrogen-
bonding in controlling the structures of crystals. The use of graph-sets in describing these 
motifs has been useful in understanding crystal structure and comparing and contrasting 
sets of molecules. The terminology proposed by Etter et al., 1990 has been in use for the 
past twenty years.14 
In 2002, Fomulu et al. proposed several considerations for the design and 
synthesis of quasiracemates using Fredga’s quasiracemates as a starting point.11 These 
considerations include the fact that the two quasienantiomers need to be isosteric, unique 
in chemical composition, and opposite in handedness. In addition, it is helpful to have a 
high degree of similarity between the two components with the presence of hydrogen 
donor and acceptor groups.11 These factors are relevant to our study of quasienantiomers 
of oxadiazinanones. 
 
Terminology and Basic Principles 
 Knowledge of basic terminology and principles are important to the 
understanding of this research; therefore, it is worthwhile to include a review.  
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Enantiomers are compounds which have the same chemical formulas and the same 
constitutions, but have different three-dimensional structures which are related by a 
mirror plane as noted in Figure 1.3. 
 
 
CH3
(S)
Br
H
HO2C
CH3
(R)
Br
H
CO2H
 
 
Figure 1.3  On the left is (S)-2-(2-bromo)propionic acid and on the right is (R)-2-(2-
bromo)propionic acid. 
 
 
The IUPAC definition for a racemate is a composite of equimolar quantities of both 
enantiomers of a compound.3, 7 Because of the equimolarity of the enantiomers, a racemic 
mixture will not have optical activity as noted by Pasteur.6  
A quasiracemate is a compound composed of two “almost” or similar 
enantiomers. There is some ambiguity in the definition due to the use of the word, 
“similar.” In an article by Fumulo et al., the definition is worded as “a molecular crystal 
derived from a true racemate by a not-too-extensive change in the structure of one of the 
two enantiomeric components.”11 How similar do the enantiomers need to be? The two 
molecules in Figure 1.4 are almost alike differing only by the Br or Cl atom. The bromine 
in the structure on the left has been replaced by chlorine in the structure on the right, as 
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indicated by the arrows. The two molecules in Figure 1.5 also differ at only one point, but 
the difference involves many more atoms.  
 
 
Figure 1.4  Quasienantiomers which differ only because one molecule has a Cl atom 
instead of a Br atom. The dotted line represents a mirror plane. 
 
 
 
Figure 1.5  Quasienantiomers which only differ in the presence of a methyl group in 
one(top) and a tri-isopropyl silyl ether functional group in the other (bottom). The dotted 
line represents a mirror plane.7 
 
 
 Comparing Figures 1.4 and 1.5, one can see there is a much greater difference 
between the quasienantiomers in Figure 1.5 than those in Figure 1.4. The methyl (Me) 
N
OO
Ph
O S
O
O
Me
N
OO
Ph
O S
O
O O
Si
CH 3 
(S) 
Br 
H 
HO 2 C 
CH 3 
(R) 
Cl 
H 
CO 2 H 
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group in the structure on top in Figure 1.5 has been exchanged for a tri-isopropyl silyl 
ether group in the bottom structure. Although all of the other atoms in the structures are 
identical in identity and location, the molecules seem to be quite different. 
  It is difficult, therefore, to define quasiracemate in a very specific manner. To 
crystallographers, the definition most generally refers to a crystal comprised of 
compounds that are very nearly enantiomers with differences of a small number of atoms. 
This is a very “loose” definition as the “small number” can vary greatly. To synthetic 
chemists, the difference in the quasienantiomers could be a small such as the difference 
in a methyl and an isopropyl group or, at the other extreme, the difference could be very 
large like the difference between a methyl and a polystyrene group.  In the present 
research, a general supposition has been made that the quasienantiomers are closely 
related and able to form a co-crystal. 
 Crystallography has a unique vocabulary and a short review may prove to be 
helpful. Crystals are an arrangement of atoms repeating in a three-dimensional pattern.15 
The arrangement can go infinitely in all directions by repeating the basic unit of the 
crystal. This basic unit is called the unit cell. Each unit cell has the same atomic contents 
arranged in the same way.  The atoms within the unit cell can be further reduced to an 
asymmetric unit. An asymmetric unit is the smallest unit of volume that contains all of 
the structural  information about the crystal. By applying symmetry operations to the 
asymmetric unit, such as inversion, translation, reflection, etc., the unit cell can be 
reproduced. The number of molecules in the asymmetric unit is designated by Z’ and the 
number of molecules in the unit cell is designated as Z.15  
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Oxadiazinanone-What is in a Name?  
The typical nomenclature of the oxadiazinanones can be confusing as one looks 
over the literature of the last thirteen years. This is evidenced by looking at the titles of 
papers authored or co-authored by Dr. G.M. Ferrence. In 2001, research involving 
3,4,5,6-tetrahydro-2-H-1,3,4-oxadiazin-2-one was reported.16 In articles published in 
2002,  research was also published reporting N3-substituted [1,3,4]-oxadiazinan-2-ones.17 
In 2004, one finds research on a group of compounds called oxadiazinones.18 In 2008, 
two papers were written on research involving chirality and substituted 1,3,4-
oxadiazinan-2-ones.19a,19b  In 2009 a paper was published on (5S,6R)-4-isopropyl-5-
methyl-6-phenyl-3-propanoyl-2H-1,3,4-oxadiazinan-2-one.20 A slight variation is found 
in 2009 when the compound is a thione instead of a ketone. In this case the nomenclature 
changes to (5S,6R)-5-methyl-6-phenyl-4-propyl-1,3,4-oxadiazinane-2-thione.21  Why the 
differences? What do the different names mean?  
IUPAC recommends using the Hantzsch-Widman nomenclature in the naming of 
heterocycles.22 The rings are named by combining prefixes with a stem. In the case of 
oxadiazinanones, the prefix ‘oxa’ refers to the oxygen atoms in the ring and the ‘az’ to 
the nitrogen atoms in the ring; the ‘di’ reflects the fact there are two nitrogen atoms.  The 
order of the names of the heteroatoms is dictated by IUPAC as O, N, and, then, S. Other 
atom preferences are listed in the literature.23 Typically the ‘az’ would be ‘aza,’ but 
phonetics dictates the omission of the final ‘a.’ This type of omission is called eliding. 
The stem for a saturated 6-member heterocycle with nitrogen and oxygen in the ring is 
‘inane’ but in the case of these compounds the final ‘e’ is omitted, again, for phonetic 
reasons. In some cases the stem ‘inane’ is changed to ‘ine’ and the saturated atoms that 
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are present in the compound are denoted by using terms such as ‘tetrahydro,’ or 
‘dihydro.’  Because oxadiazinanones are ketones, the name of the compound ends in 
‘one.’ The numbering in heterocyclic rings becomes necessary when substituents are 
placed on the ring. The numbering begins with a hetero-atom, and then the substituents 
are numbered so that the lowest combination of numbers is assigned. The substituents are 
placed in alphabetical order. The positions of the substituents play no role in the order of 
the numbering. The substituents are included in alphabetical order preceded by the 
number of the atom to which they are attached.23 In addition to these rules, unsaturated 
atoms located in the ring are designated by using ‘H.’ This reflects that the parent hydride 
would have hydrogen atoms in this position. 
Using the compound in Figure 1.6 as an example, the proper nomenclature will be 
discussed. In this heterocycle the chirality is described by (5S,6R). 
 
 
 
Figure 1.6  Line drawing of (5S,6R)-4-cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one. 
 
 
The substituents are listed in alphabetical order with the number of the atom to which 
they are attached preceding the name of the substituent. The order of the atom numbers is 
chosen by starting with the oxygen atom as atom 1 and then numbering the rest. This 
O
(R)
(S)
N
NH
O
1
2
3
4
5
6
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numbering scheme results in the lowest combination of position-numbers of heteroatoms 
as possible. The 2H indicates an atom where the parent hydride would have hydrogen 
atoms affixed, but it does not in this molecule because of the carbonyl group.  The “1,3,4-
oxadiaz” portion of the name refers to the oxygen atom and two nitrogen atoms in the 
heterocycle. The substituents are arranged in alphabetical order preceded by the atom 
number to which they are attached. The prefix, “inan,” refers to a saturated heterocycle 
containing nitrogen. The stem, “2-one,” refers to the fact that this is a ketone with the 
carbonyl on atom 2. 
Why Study Quasiracemates? 
Some reasons for the study of quasienantiomers given in a review by Zhang and 
Curran are that they can be used as tools for enantiomer identification, enantiomer 
analysis, separation of chemical components and enantiomer synthesis.7 Although all of 
these pragmatic uses are valuable, the current study is more esoterically focused on how 
and why oxadiazinanones form quasiracemates. This is related to the discussion of 
Fomolu and co-workers about the study of quasiracemates in the field of supramolecular 
chemistry. Using comparisons of quasiracemate, enantiomer, and racemate crystals, the 
molecular architecture can be studied.11 The database of quasiracemic crystals needs to 
be as large as possible in order to determine general principles which cause the 
crystallization of quasiracemic crystals. 
Additionally, oxadiazinanones have been synthesized fairly easily using methods 
developed by Hitchcock and his group.24, 25 Decent yields have been reported. The 
compounds are easily purified with flash chromatography. Optically pure norephedrine or 
ephedrine starting materials result in optically pure substituted oxadiazinanones. 
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Previous Quasiracemic Crystal Research 
The research group of Dr. Shawn Hitchcock at Illinois State University has 
synthesized and studied a variety of oxadiazinanones as a route to forming chiral 
auxiliaries for pharmaceutical studies.25 In an effort to understand some principles of 
crystal structure and chirality, Kate Edler used these immediately-available 
oxadiazinanones in her research.26 In the course of the research, serendipitously, she 
mixed together norephedrine-based (5S,6R)-4-isopropryl-5-methyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one and (5R,6S)-4-cyclohexyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-
2-one in approximately equal molarities. These crystals resulted in the first of the 
quasiracemic oxadiazinanone crystals studied by the Ferrence group.26   
Ignoring epimers, there are two oxadiazinanone enantiomers for each 
norephedrine derived N-4-substituted variant. Figure 1.7 shows a line drawing of 
(5R,6S)-6-phenyl-4-R-(1,3,4)-oxadiazin-2-one. The arrow points to the nitrogen with the 
substituted variant. 
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Figure 1.7  Line drawing of (5R,6S)-4-R-5-methyl-6-phenyl-1,3,4-oxadiazinan-2-one. 
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For example, using the cyclopentyl functional group, the two oxadiazinanone 
structures in Figure 1.8, when crystallized, form a racemic crystal. 
 
O
(S)
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(S) N
N
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Figure 1.8  Line drawing of (left) (5R,6S)-4-cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one and (right) (5S,6R)-4-cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one. 
 
 
If an isopropyl group is substituted for the cyclopentyl group (structure on the left 
in Figure 1.8) and a cyclohexyl group for the cyclopentyl group (structure on the right), 
the resulting compounds are shown in Figure 1.9. These compounds cocrystallize 
forming a quasiracemic crystal. 
 
N
NO
O
H
CH3
             
N
NO
O
H
CH3
                                                               
Figure 1.9  Line drawings of (left) (5R,6S)-4-isopropryl-5-methyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one and (right) (5S,6R)-4-cyclohexyl-5-methyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one. 
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The fact that the oxadiazinanones in Figure 1.9 formed quasiracemic crystals begs 
the question: would other oxadiazinanones do so as well? To further explore the 
possibility, it was necessary to acquire a number of oxadiazinanones which varied at the 
N4 position in both (5S,6R) and (5R,6S) configurations.  
The synthesis of these compounds uses either ephedrine (for methyl-substitution) 
or norephedrine as a starting reactant.27 The resulting oxadiazinanone quasienantiomers 
are then mixed and crystallized in an attempt to form the corresponding quasiracemate. 
Finally, the crystal structures are studied in an attempt to determine what causes some 
oxadiazinanone quasienantiomers to cocrystallize and others to fractionally crystallize.
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CHAPTER II 
EXPERIMENTAL 
Synthesis of Oxadiazinanones Used in Crystallographic Studies 
All oxadiazinanone compounds used in this research were either acquired from 
the lab of  Dr. Shawn Hitchcock or synthesized using procedures, or adaptations thereof, 
devised by the Hitchcock group.27  The compound, (5R,6S)-4-cyclopentyl-5-methyl-6-
phenyl-2H-1,3,4-oxadiazinan-2-one, and its precursors are newly-synthesized products.  
The synthesis of the ethyl derivative of the oxadiazinanone and the n-butyl derivative of 
the oxadiazinanone, instead of producing the desired oxadiazinanones, resulted in newly-
synthesized noncyclized compounds. In addition to these newly-synthesized compounds, 
two new quasiracemates were formed when (5R,6S)-4-cyclopentyl-5-methyl-6-phenyl-
2H-1,3,4-oxadiazinan-2-one was crystallized with (5S,6R)-4-cyclohexyl-5-methyl-6-
phenyl-2H-1,3,4-oxadiazinan-2-one and separately with (5S,6R)-4-isopropyl-5-methyl-6-
phenyl-2H-1,3,4-oxadiazinan-2-one. 
The synthesis of oxadiazinanones includes four main steps: alkylation, 
nitrosation, hydrazine-formation, and cyclization. Figures 2.1, 2.3, 2.5, and 2.6 show the 
steps in the reaction using the cyclopentane derivative as an example: Figure 2.2 gives 
the mechanism for the reductive alkylation. Table 2.1 shows which alkyl groups were 
added to N4 as a substituent.
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Figure 2.1  Step 1: Reductive alkylation of (1S,2R) norephedrine. 
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Figure 2.2  Mechanism for the reductive alkylation of an amine.28 
 
 
Table 2.1  Aldehydes and ketones used in the synthesis of N4 substituted norephedrine.  
 
N4 Substituent Reactant 
ethyl acetaldehyde 
n-propyl propanal 
isopropyl acetone 
n-butyl butanal 
cyclohexyl cyclohexanone 
cyclopentyl cyclopentanone 
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 Figure 2.3 shows the reaction for the nitrosation of the alkylated norephedrine and 
the mechanism for the reaction is shown in Figure 2.4. 
OH
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O
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(S)
(R)
N
H NaNO2, HCl
THF
Cyclopentyl derivative 
of (1S,2R)norephedrine
Nitrosated cyclopentyl 
derivative of
(1S,2R)norephedrine  
 
Figure 2.3  Step 2: Nitrosation of the alkylated derivative of (1S,2R) norephedrine. 
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Figure 2.4  Mechanism for the nitrosation of an alkylated norephedrine.28  
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The nitrosate of the alkyl derivative of the norephedrine is part of a group of 
compounds known to be carcinogenic, so great care must be used to avoid contact with 
the compound during the synthesis.29  
At the conclusion of Steps 1 and 2, 1H nuclear magnetic resonance spectroscopy 
(1H NMR) analysis is used to ascertain that the proper product is formed in sufficient 
purity to continue the synthesis. When the product is not what is expected or is in low 
yield, typically, the step can be repeated to obtain the desired product and the synthesis 
can continue.  When purification of the product is needed, flash chromatography is 
utilized. 
 
 
Figure 2.5  Step 3: Hydrazine-formation from the reduction of  the nitrosate of the alkyl 
derivative of (1S,2R) norephedrine. 
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Figure 2.6 Step 4: Cyclization of the hydrazine forming the 1,3,4 oxadiazinanone. 
 
 
 Steps 3 and 4 are completed with as little delay between them as possible because 
the hydrazine is not stable. 1H NMR testing is typically not done after Step 3 as the 
hydrazine cannot be purified at this point and remain stable, so the synthesis must 
continue. Bentley, in his thesis, proposed mechanisms for the third and fourth steps of the 
procedure; these will not be further explored here.28 
Change in 1H NMR After Nitrosation of Alkyl Derivative 
 The rotamer diastereomers for the nitrosate are shown in Figure 2.7. The rotamer 
on the right results in having a doublet at 0.8 ppm in the 1H NMR spectrum. The rotamer 
on the left results in a second doublet further downfield at 1.6 due to the shielding of the 
oxygen atom in the nitrosate. According to Hitchcock, Casper et al.29 the two rotamers 
exist because the resonance of the N=O bond in the structure creates a barrier to rotation 
of the N-N=O moiety. The N-N bond does not rotate until very high temperatures are 
obtained so both rotamer diastereomers occur simultaneously in the nitrosate of the 
alkylated derivative of norephedrine. These two rotamers  help to verify the presence of 
the nitrosate.  
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The 1H NMR spectra of the alkylated derivative, as seen in Figure 2.8, has a 
doublet at 0.8 ppm indicating the presence of the methyl group. However, when the N-
nitroso amine is formed in the second step of the synthesis, the 1H NMR spectra in Figure 
2.9 shows two doublets for the methyl group—one doublet at 0.83 ppm and one 
downfield at 1.6`. This results from the formation of two diastereomeric rotamers (Figure 
2.7) which exist as major and minor species in the product.  
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Figure 2.7 The (E)-rotamer (left) and the (Z)-rotamer (right) of the nitrosamines of the  
cyclopentyl derivatives of (1S,2R) norephedrine. 
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Figure 2.8 1H NMR spectrum of the cyclopentyl derivative of (1S,2R) norephedrine. 
  
1.52.02.53.03.54.04.55.05.56.06.57.07.5 ppm
1.01.52.0 ppm
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Figure 2.9 1H NMR spectrum of the nitrosate of the cyclopentyl derivative of (1S,2R) 
norephedrine. Note the presence of the two doublets caused by the two different nitrosate 
rotamers. 
 
 
Experimental Procedure for the Synthesis of (5R,6S)-4-Cyclopentyl-5-methyl-6-
phenyl-2H-1,3,4-oxadiazinan-2-one, 1  
 
Alkylation: (1S,2R) norephedrine (10.00 g, 66.13 mmol) and cyclopentanone (7.00 g, 
83.2 mmol) were added to a nitrogen-purged, 1 L round-bottom flask with ethanol (100 
mL). The mixture was refluxed for 24 hours, cooled in an ice bath and NaBH4 (6.26 g, 
165 mmol) was added over a period of approximately 30 minutes. The flask was removed 
from the ice and ethanol was added (100 mL). After the mixture was stirred for an 
additional 2.5 hours, 1M NaOH (100 mL, 100 mmol) was added. Ethanol was removed 
from the solution using rotary evaporation, and the product was extracted with ethyl 
acetate, washed with brine, and dried over sodium sulfate resulting in the cyclopentyl 
1.52.02.53.03.54.04.55.05.56.06.57.07.5 ppm
ppm
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derivative of (1S,2R) norephedrine (13.73 g, 76.24 mmol). 1H NMR spectroscopy was 
used to ascertain the purity of the sample, and it was determined that the product was not 
fully alkylated. The product was then refluxed overnight under the same conditions and 
with the same reagents as described previously resulting in the desired product.   
Nitrosation: The cyclopentyl derivative of (1S,2R) norephedrine was nitrosated by adding 
3M HCl (25 mL, 75 mmol) to the alkylated norephedrine. Approximately 60 mL of 
tetrahydrofuran (THF) was added, and the mixture was stirred. To the mixture NaNO2 
(5.5 g, 79 mmol) was added. The solution turned pink. The reaction was allowed to 
proceed for 4 days. Sodium bicarbonate (saturated solution) was added to reach a pH of 
8. THF was removed by rotary evaporation. The final product was extracted with ethyl 
acetate, washed with brine and dried over Na2SO4. The ethyl acetate was removed by 
rotary evaporation resulting in the nitrosated cyclopentyl derivative of (1S,2R) 
norephedrine (8.19 g, 33.0 mmol). One gram was removed for further research and the 
rest of the product was reduced. 
Reduction: Hexanes (200 mL) were added to a flame-dried, nitrogen-purged, 2 L round-
bottom flask.  Lithium aluminum hydride (2.29 g, 60.3 mmol) was added to the flask 
followed by the addition of THF (approximately 600 mL). The nitrosated cyclopentyl 
derivative of (1S,2R) norephedrine (7.19 g, 29.0 mmol) was dissolved in THF (100 mL) 
and added, dropwise, to the flask. The reaction was gently refluxed for three hours, and, 
then, cooled in an ice bath. Then, 1M NaOH (200 mL, 200 mmol) was added. Rotary 
evaporation was used to remove the THF. The product was extracted with ethyl acetate, 
washed with Rochelle’s solution and brine, and dried over NaSO4. The ethyl acetate was 
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removed by rotary evaporation resulting in the hydrazine, an oily, yellow product (5.24 g, 
22.4 mmol). 
Cyclization: The hydrazine was dissolved in hexanes (144 mL) in a flame-dried, nitrogen-
purged 1 L round-bottom flask. Diethyl carbonate (2.98 mL, 24.6 mmol) was added to 
the flask and the solution was refluxed under nitrogen for 16 hours. The resulting product 
was cooled in an ice bath and the hexanes were removed by rotary evaporation. The 
resulting product was dissolved in ethyl acetate (123 mL), washed with 1M HCl (3 x 
15mL) and brine, and dried over sodium sulfate. Rotary evaporation was used to remove 
the ethyl acetate and a yellow, oily solid was obtained (5.16 g). Crystallization of the 
final product was achieved by dissolving the product in ethyl acetate and adding hexanes 
as an anti-solvent, resulting in a crystalline product (1.18 g, 4.53 mmol). The percent 
yield was 6.85%. 
Experimental Procedure for the Intended Synthesis of (5R,6S)-4-Ethyl-5-methyl-6-
phenyl-2H-1,3,4-oxadiazinan-2-one, 5 
 
The synthesis of  (5R,6S)-4-ethyl-5-methyl-6-phenyl-2H-1,3,4-oxodiazinanan-2-
ne proved to be problematic. Using acetaldehyde was difficult because it has such a low 
boiling point that it evaporated before the reaction occurred. Thus acetic anhydride was 
used, producing an amide derivative which was then reduced by NaBH4 and I2 followed 
by nitrosation.24 This method resulted in a mixture of the amide and amine and other 
unknown compounds. Two grams of the amide were produced to use for future study. 
The initial procedure was once again tried with a large excess of acetaldehyde. The 
acetaldehyde was stored in a freezer at 0 °C prior to use. Nitrosation followed and flash 
chromatography was used to purify the nitrosated compound. The 1H NMR spectrum 
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indicated the proper compound was made. However, after the product was reduced, 
cyclized and then purified using flash chromatography, X-ray diffraction analysis 
determined the structure in Figure 2.10. This structure indicates the cyclization had not 
been completed. The specifics of the synthesis follow. 
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Figure 2.10  Line drawing of 5. This is not an oxadiazinanone, but the product of an 
oxadiazinanone reaction which did not cyclize. 
 
 
Alkylation: (1S,2R) norephedrine (10.00 g, 66.13 mmol) and acetaldehyde (7.4 mL, 130 
mmol) and ethanol (100 mL) were added to a nitrogen-purged, 1L round-bottom flask. 
The syringe used to add the acetaldehyde was placed in the freezer before use in an 
attempt to reduce the evaporation of the aldehyde. The mixture was refluxed for 24 hours 
and cooled in an ice bath. NaBH4 (6.24 g, 165 mmol) was added over a period of 
approximately 30 minutes. The flask was removed from the ice and ethanol was added 
(100 mL). After the mixture was stirred for an additional 2.5 hours, 1M NaOH (100 mL, 
100 mmol) was added. Ethanol was removed using rotary evaporation. The resulting 
product was extracted with ethyl acetate, washed with brine, and dried over sodium 
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sulfate resulting, in the ethyl derivative of (1S,2R) norephedrine (11.91 g, 66.50 mmol). 
1H NMR analysis revealed the product was pure and nitrosation could take place. 
Nitrosation: The ethyl derivative of (1S,2R) norephedrine was nitrosated by, first, adding 
3M HCL (25 mL, 75 mmol) to the alkylated product and then adding THF (50 mL). The 
mixture was stirred. Sodium nitrite (5.6 g, 79 mmol) was added and the reaction was 
allowed to stir overnight. The solution was orange-brown in color. Sodium bicarbonate 
(saturated solution, 50 mL) was added until the solution reached a pH of 8. THF was 
removed by rotary evaporation. The final product was extracted with ethyl acetate, 
washed with brine, and dried over Na2SO4. The ethyl acetate was removed by rotary 
evaporation resulting in the nitrosated ethyl derivative of (1S,2R) norephedrine. 1H NMR 
spectroscopy indicated the product needed purification. This was accomplished using 
flash chromatography resulting in the final crystalline product. (3.97 g, 19.1 mmol). 
Reduction: Hexanes (200 mL) were added to a flame-dried, nitrogen-purged, 2L round-
bottom flask.  Lithium aluminum hydride (0.9737 g, 38.15 mmol) was added to the flask 
followed by the addition of THF (600 mL). The nitrosated ethyl derivative of (1S,2R) 
norephedrine (3.97 g, 19.1 mmol) was dissolved in THF (100 mL) and added, drop-wise, 
to the flask. The reaction was gently refluxed for three hours, cooled in an ice bath, and 
1M NaOH (200 mL, 200 mmol) was added. Rotary evaporation was used to remove the 
THF, and the product was extracted with ethyl acetate andwashed with Rochelle’s 
solution. Then it was washed with brine, and dried over NaSO4. The ethyl acetate was 
removed by rotary evaporation resulting in the hydrazine, an oily, yellow product (2.49 g, 
12.8 mmol). 
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Cyclization: The hydrazine was dissolved in hexanes (144 mL) in a flame-dried and 
nitrogen-purged 1L round-bottom flask. Diethyl carbonate (1.7 mL, 21 mmol) was added 
to the flask and the solution was brought to reflux. Lithium hydride (0.33 g, 42 mmol) 
was added slowly and the solution was refluxed under nitrogen overnight. The resulting 
product was cooled and hexanes were removed by rotary evaporation. The resulting 
product was dissolved in ethyl acetate (123 mL), washed with 1M HCl, washed with 
brine, and dried over sodium sulfate. Rotary evaporation was used to remove the ethyl 
acetate and a yellow, oily compound was obtained (5.16 g). The resulting product was 
dissolved in ethyl acetate and hexanes were added to cause the product to crystallize 
(2.19 g, 9.95 mmol). The percent yield was 15.1%. 
Experimental Procedure for the Intended Synthesis of (5R,6S)-4-Ethyl-5-methyl-6-
phenyl-2H-1,3,4-oxadianinan-2-one, 6 
 
In an attempt to synthesize (5R,6S)-4-ethyl-5-methyl-6-phenyl-2H-1,3,4-
oxadiazinanan-2-one using standard literature procedures27 the compound depicted in the 
ChemDraw30 figure in Figure 2.11 was synthesized and was identified using X-ray 
diffraction indicating the cyclization reaction had not gone to completion. 
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Figure 2.11  Line drawing of 6. This is not an oxadiazinanone, but, instead is the product 
of an oxadiazinanone reaction which did not cyclize. 
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Alkylation: (1S,2R) norephedrine (10.00 g, 66.13 mmol), butanal (7.2 mL,  80 mmol) and 
ethanol (100 mL) were added to a nitrogen-purged, 1L, round-bottom flask. The mixture 
was refluxed for 24 hours and cooled in an ice bath. NaBH4 (6.26 g, 165 mmol) was 
added over a period of 30 minutes. The flask was removed from the ice and ethanol was 
added (100 mL). The mixture was stirred for an additional 2.5 hours, and 1M NaOH (100 
mL, 100 mmol) was added. Ethanol was removed from the solution using rotary 
evaporation, and the product was extracted with ethyl acetate, washed with brine, and 
dried over sodium sulfate resulting in the n-butyl derivative of (1S,2R) norephedrine. The 
product was purified with flash chromatography. 
Nitrosation: The n-butyl derivative of (1S,2R) norephedrine was nitrosated by dissolving 
the alkylated norephedrine in 3M HCl (25mL, 75mmol. THF (60 mL) was added and the 
mixture was stirred while NaNO2 (5.5 g, 79 mmol) was added. The reaction proceeded 
under reflux overnight. Sodium bicarbonate (saturated solution) was added to the flask 
until a pH of 8 was reached. Rotary evaporation was used to remove the THF. The final 
product was extracted with ethyl acetate, washed with brine, and dried over Na2SO4. The 
ethyl acetate was removed by rotary evaporation resulting in the nitrosated n-butyl 
derivative of (1S,2R) norephedrine. Flash chromatography was used to purify the product 
(5.13 g, 21.7 mmol). 
Reduction: Hexanes (200mL) were added to a flame-dried, nitrogen-purged, 2L round-
bottom flask.  Lithium aluminum hydride (2.47 g, 65.1 mmol) was added to the flask 
followed by the addition of THF (135 mL). The nitrosated n-butyl derivative of (1S,2R) 
norephedrine (5.13 g, 21.7 mmol) was dissolved in THF (50 mL) and added, dropwise, to 
the flask. The reaction was refluxed for an additional two hours. The reaction was cooled 
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in an ice bath and 3M NaOH (40 mL, 100 mmol) was added. THF was removed using 
rotary evaporation. The hydrazine was extracted with ethyl acetate, washed with 
Rochelle’s solution and brine, and dried over NaSO4. The ethyl acetate was removed by 
rotary evaporation resulting in an oily, yellow product (4.83 g, 21.7 mmol). 
Cyclization: The hydrazine was dissolved in hexanes (200 mL) in a nitrogen-purged, 
flame-dried, 1L round-bottom flask. Diethyl carbonate (2.82 mL, 23.8 mmol) was added 
to the flask and the solution was brought to reflux under nitrogen. Lithium hydride (0.35 
g, 44 mmol) was added, and the solution was refluxed overnight. The resulting product 
was cooled in an ice bath, and hexanes were removed with rotary evaporation. The 
resulting product was dissolved in ethyl acetate (123 mL), washed with 1M HCl, then 
with brine, and dried over sodium sulfate. Rotary evaporation was used to remove the 
ethyl acetate, and a yellow, oily solid was obtained (4.41 g). The oil was purified using 
flash chromatography resulting in a white crystalline product (5.17 mmol, 7.82% yield). 
Crystallization Procedure 
 Single crystals were formed using vapor diffusion.  If a pure compound was being 
crystallized, a sample of approximately 0.008 g was placed in an uncapped inner vial in 
0.5 mL of solvent. If a racemate or quasiracemate was being crystallized, a mixture of the 
compounds was used with a total weight of approximately 0.008 g. Since the molecular 
weights of the oxadiazinanones are similar, this provided nearly equimolar solutions with 
concentrations of approximately 3 x 10-5 M for each component. If just one compound 
was being crystallized, this provided a 6 x 10-5 M concentration. Into an outer vial was 
placed 2.5 mL of the anti-solvent, hexanes (boiling point, 69 °C. The crystals are not 
soluble in hexanes. The outer vial was then closed, allowing the solvent and anti-solvent 
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to equilibrate by vapor diffusion. Ethyl acetate (boiling point, 77 ⁰C) was used as the 
solvent. In this system the hexanes diffuse into the inner vial. At the same time there is a 
slow diffusion of the solvent out of the inner vial into the hexanes. The oxadiazinanones 
are not as soluble in hexanes as in ethyl acetate. Because the diffusion taking place in the 
system increases the concentration of hexanes in the inner vial, crystals slowly form.31   If 
crystallization of the oxadiazinanones did not happen after 2 to 3 days, the hexanes were 
removed and replaced with fresh hexanes. Usually, crystals formed within 2 to 3 days at 
room temperature.  
X-Ray Diffraction 
X-ray structures were obtained by selecting a suitable crystal using a dissecting 
microscope. The dimensions of most crystals were approximately 0.2 mm to 0.4 mm on 
each side. The crystals were then mounted using mineral oil as an adherent on MiTeGen 
Micromounts with loops or MicroMesh aperatures. The mount was attached to the 
goniometer head and mounted on a Bruker Apex II diffractometer.  Mo-Kα radiation 
(λ=0.71073 Å) was used for the collection of the data. The sample was generally kept at 
100K during data collection. For some samples, additional information was gained by 
varying the temperature during collection as indicated in the experimental details about 
each compound. All data were collected using the software program, SAINT, and refined 
using SMART+.32 Solution and data analysis were completed using the WinGX software 
package.33 The structures were solved using direct methods employing the programs, 
SIR200434 or SuperFlip.35 The refinement was accomplished using SHELXL-2012.36 The 
non-hydrogen atoms were refined anisotropically and, in most cases, the hydrogen atoms 
were assigned using a riding-model approximation. Hydrogen atoms attached to nitrogen 
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atoms were freely refined unless indicated otherwise in the experimental details for each 
compound.
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CHAPTER III 
 
CRYSTALLOGRAPHIC RESULTS 
 
Crystallographic Details of (5R,6S)-4-Cyclopentyl-5-methyl-6-phenyl-2H-1,3,4- 
oxadiazinan-2-one, 1 
 
 Figure 3.1 shows a ChemDraw30 depiction of  (5R,6S)-4-cyclopentyl-5-methyl-6-
phenyl-2H-1,3,4-oxadiazinan-2-one (1). 
 
O
(S)
(R)
N
CH3
NH
O
 
Figure 3.1 Line diagram of 1. 
 
 
The dimensions of the crystal used for X-ray diffraction were 0.360 mm x 0.270 mm x 
0.210 mm. The sample was g kept at 100K during the diffraction experiment. Shelxl-
201236 was used for refinement.  The unit cell parameters were obtained from a least-
squares refinement of 4581 unique reflections out of the 17571 reflections collected. The 
crystal is orthorhombic and crystallizes in the P212121 space group. The cell lengths are:  
a = 8.4171(3) Å, b = 9.0618(4) Å, and c = 36.7815(13) Å. The volume of the cell is 
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2805.47 Å3 and ρ = 1.233 g/cm3.  Z’ is 2 and Z is 8.  Diffraction data were measured 
between θmin = 1.107° and θmax = 25.352°.  The limiting indices were -10 ≤ h ≤ 10, -10 ≤ k 
≤ 10, and -44 ≤ l ≤ 44. All hydrogen atoms attached to nitrogen were freely refined and 
all other hydrogens were refined using the riding-model approximation. Convergence 
was reached on the full-matrix least-squares refinement of F2. The R1-factor is 0.0432 
and wR2 is 0.1029. Figure 3.2 shows an ORTEP33 depiction of 1. The ellipsoids are at 
50% and the hydrogen atoms have been omitted for clarity. The hydrogen bonds are 
shown as dotted lines. 
 
 
Figure 3.2  Ellipsoid depiction of 1. 
 
 
The bond lengths, bond angles and torsion angles of the central oxadiazinanone 
ring as well as any carbon atoms attached to the ring are shown in Tables 3.1-3. Table 3.4 
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shows the hydrogen bond lengths. Molecule 1 refers to the molecule with the lower range 
of atom numbers. This is the molecule on the right side in Figure 3.2. 
 
Table 3.1  Bond lengths of the central oxadiazinanone rings in the asymmetric unit of 1. 
 
Atoms (Molecule 1) Distance (Å) Atoms (Molecule 2) Distance (Å) 
O1-C2 1.356(4) O51-C52 1.356(4) 
O1-C6 1.463(4) O51-C56 1.455(4) 
C2-O19 1.223(4) C52-O69 1.224(4) 
C2-N3 1.336(4) C52-N53 1.338(4) 
N3-N4 1.424(4) N53-N54 1.428(4) 
N4-C14 1.479(4) N54-C64 1.490(4) 
N4-C5 1.470(4) N54-C55 1.466(4) 
C5-C6 1.542(5) C55-C56 1.534(5) 
C5-C13 1.516(5) C55-C63 1.517(5) 
C6-C7 1.499(5) C56-C57 1.507(5) 
 
 
Table 3.2  Bond angles of the central oxadiazinanone rings in the asymmetric unit of 1. 
    Atoms (Molecule 1) Angle (°) Atoms (Molecule 2) Angle (°) 
C6-O1-C2 121.1(3) C56-O51-C52 121.6(3) 
O1-C2-N3 118.7(3) O51-C52-N53 118.6(3) 
O1-C2-O19 117.5(3) O51-C52-O69 117.9(3) 
O19-C2-N3 123.8(3) O69-C52-N53 123.5(3) 
C2-N3-N4 125.9(3) C52-N53-N54 124.7(3) 
N3-N4-C5 108.5(2) N53-N54-C55 107.0(2) 
C14-N4-C5 114.9(3) C64-N54-C55 117.0(3) 
N4-C5-C13 109.4(3) N54-C55-C63 110.0(3) 
C13-C5-C6 114.3(3) C63-C55-C56 114.1(3) 
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Table 3.3  Torsion angles of the central oxadiazinanone rings in the asymmetric unit of 1. 
 
Atoms (Molecule 1) Torsion (°) Atoms (Molecule 2) Torsion (°) 
C6-O1-C2-N3 1.5(4) C56-O51-C52-N53 -7.4(5) 
C6-O1-C2-O19 179.1(3) C56-O51-C52-O69 172.0(3) 
C2-O1-C6-C5 -26.7(4) C52-O51-C56-C55 -20.4(4) 
C2-O1-C6-C7 -151.2(3) C52-O51-C56-C57 -143.8(3) 
O1-C2-N3-N4 -4.1(5) O51-C52-N53-N54 1.1(5) 
O19-C2-N3-N4 178.4(3) O69-C52-N53-N54 -178.3(3) 
C2-N3-N4-C5 32.5(4) C52-N53-N54-C55 33.0(4) 
C2-N3-N4-C14 -92.5(4) C52-N53-N54-C64 -94.1(4) 
N3-N4-C5-C6 -55.3(3) N53-N54-C55-C56 -58.8(3) 
N3-N4-C5-C13 70.7(3) N53-N54-C55-C63 67.4(3) 
C14-N4-C5-C6 65.8(3) C64-N54-C55-C56 63.1(3) 
C14-N4-C5-C13 -168.2(3) C64-N54-C55-C63 -170.8(3) 
N4-C5-C6-O1 54.1(3) N54-C55-C56-O51 54.1(3) 
N4-C5-C6-C7 175.0(3) N54-C55-C56-C57 175.2(3) 
 
 
Table 3.4  Donor-Acceptor Hydrogen bond lengths in 1. 
Donor-Acceptor Distance, D-A (Å) Bonding Motif 
N53-O19 2.879 
Different Enantiomorph 
O69-N3 2.888 
 
 
 
Crystallographic Details of Racemic 4-Cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one, 2 
Compound 2 was prepared by combining equal amounts of each enantiomer of 4-
cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one. The two enantiomers are 
shown in Figure 3.3. The enantiomer on the left is the ChemDraw30 depiction of (5R,6S) 
configuration and on the right is the ChemDraw30 depiction of (5S,6R) enantiomer. 
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Figure 3.3  Line drawings of the two enantiomers of 2. 
 
 
The temperature was 292 K. Shelxl-201236 was used for refinement.  The unit cell 
parameters were obtained from a least-squares refinement of 2460 unique reflections out 
of the 19297 reflections collected. The crystal is monoclinic and crystallizes in the P21/c 
space group. The cell lengths are: a = 9.1808(3) Å, b = 15.7560(5) Å, and c = 9.7293(3) 
Å.  The angles of the cell are: α = 90°, β = 106.132(2)°, and γ = 90°. The volume of the 
cell is 1351.95 Å3 and ρ = 1.279 g/cm3.  Z’ is 1 and Z is 4.  Diffraction data were 
measured between θmin = 2.309° and θmax = 25.300°.  The limiting indices were -11 ≤ h ≤ 
11, -18 ≤ k ≤ 18, and -11 ≤ l ≤ 11. All hydrogen atoms attached to nitrogen were freely 
refined, and all other hydrogens were refined using the riding-model approximation. 
Convergence was reached on the full-matrix least squares refinement of F2. The R1 factor 
is 0.0381 and wR2 is 0.0926.   
Figure 3.4 shows an ORTEP33 depiction of 2. The ellipsoids are at 50% and the 
hydrogen atoms have been omitted for clarity. The hydrogen bonds are shown as dotted 
lines. 
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Figure 3.4  Ellipsoid depiction of asymmetric unit of 2.  
 
 
The bond lengths, bond angles and torsion angles of the central oxadiazinanone 
ring as well as any carbon atoms attached to the ring are shown in Tables 3.5- 3.7. Each 
oxadiazinanone structure has two hydrogen bonds in the asymmetric unit.  Hydrogen 
bond distances and angles are shown in Table 3.8.  
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Table 3.5 Bond lengths in the central oxadiazinanone ring of 2.  
 
Atoms Bond Length (Å) 
O1-C2 1.354(2) 
O1-C6 1.446(2) 
C2-N3 1.333(2) 
C2-O20 1.227(2) 
N3-N4 1.429(2) 
N4-C5 1.473(2) 
C5-C6 1.533(2) 
C7-C8 1.391(3) 
 
 
Table 3.6 Bond angles of the central oxadiazinanone ring of 2. 
 
Atoms Angle (°) 
C6-O1-C2 118.5(1) 
O1-C2-N3 118.8(1) 
O1-C2-O19 117.7(1) 
O19-C2-N3 123.4(1) 
C2-N3-N4 127.5(1) 
N3-N4-C5 108.7(1) 
C14-N4-C5 114.9(1) 
N4-C5-C13 109.9(1) 
C13-C5-C6 113.0(1) 
C5-C6-O1 108.9(1) 
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Table 3.7 Torsion angles of the central oxadiazinanone ring in the asymmetric unit of 2. 
 
Atoms  Torsion (°) 
C6-O1-C2-N3 -7.7 (2) 
C6-O1-C2-O20 174.5(1) 
C2-O1-C6-C5 40.0(2) 
C2-O1-C6-C7 165.4(1) 
O1-C2-N3-N4 -6.4(2) 
O19-C2-N3-N4 171.3(1) 
C2-N3-N4-C5 -15.3(2) 
C2-N3-N4-C14 111.3(2) 
N3-N4-C5-C6 47.0(1) 
N3-N4-C5-C13 -77.9(1) 
C14-N4-C5-C6 -76.6(1) 
C14-N4-C5-C13 158.5(1) 
N4-C5-C6-O1 -60.4(1) 
N4-C5-C6-C7 178.8(1) 
C13-C5-C6-O1 62.7(1) 
C13-C5-C6-C7 -58.1(2) 
 
 
Table 3.8 Donor-Acceptor Hydrogen bond lengths in 2. 
 
Donor-
Acceptor Distance, D-A (Å) Bonding Motif 
N3-O19 2.824 Same enantiomorph 
 
 
Crystallographic Details of Quasiracemate of (5R,6S)-4-Cyclopentyl-5-methyl-6-
phenyl-2H-1,3,4-oxadiazinan-2-one and (5S,6R)-4-Isopropyl- 
5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one, 3 
 
ChemDraw30 depictions of the quasienantiomers used to produce 3 are shown in 
Figure 3.5. X-ray diffraction was used to confirm the presence of quasiracemates. 
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Figure 3.5  Line drawings of (left) (5R,6S)-4-cyclopentyl-5-methyl-6-phenyl-2H- 1,3,4-
oxadiazinan-2-one and (right)  (5S,6R)-4-cyclopentyl-5-methyl -6- phenyl-2H-3,4-
oxadiazinan-2-one. 
 
 
The temperature was 292K. Shelxl-201236 was used for refinement.  The unit cell 
parameters were obtained from a least-squares refinement of 8339 unique reflections out 
of the 52929 reflections collected. The crystal is monoclinic and crystallizes in the P21 
space group. The cell lengths are: a = 10.4323(3) Å, b = 8.7068(2) Å, and 
 c = 14.6212(4) Å. The volume of the cell is 1324.64(6) Å3 and ρ = 1.240 g/cm3. The 
angles of the cell are: α = 90°, β = 94.1200(10)°, and γ = 90°.  Z’ is 2 and Z is 2.  
Diffraction data were measured between θmin = 1.396° and θmax = 32.151°. The limiting 
indices were -15 ≤ h ≤ 15, -12 ≤ k ≤ 12, and -21 ≤ l ≤ 21. All hydrogen atoms attached to 
nitrogen were freely refined and all other hydrogens were refined using the riding-model 
approximation. Convergence was reached on the full-matrix least-squares refinement on 
F2. The R1-factor is 0.0427 and wR2 is 0.1098.  An ORTEP33 depiction in Figure 3.6. In 
each figure the hydrogen atoms have been omitted for clarity and hydrogen bonds are 
shown as dotted lines. In Figure 3.9, the ellipsoids are modeled at 50% probability.  
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Figure 3.6  Ellipsoid depiction of 3. 
 
 
The bond lengths and bond angles of the central oxadiazinanone ring of 3 are 
shown in Tables 3.9 and 3.10. In Table 3.11 are found the torsions of the central 
oxadiazinanone ring, as well as the carbons attached to the central ring. Table 3.12 shows 
the hydrogen bond distances and angles. 
 
Table 3.9 Bond lengths of the central oxadiazinanone atoms of 3.  
  
Atoms-isopropyl Bond Length (Å) Atoms-cyclopentyl Bond Length (Å) 
O1-C2 1.353(2) O51-C52 1.354(2) 
O1-C6 1.457(2) O51-C56 1.458(2) 
C2-N3 1.342(2) C52-N53 1.338(2) 
C2-O17 1.228(2) C52-O69 1.233(2) 
N3-N4 1.426(2) N53-N54 1.424(2) 
N4-C5 1.474(2) N54-C55 1.476(2) 
C5-C6 1.535(2) C55-C56 1.534(2) 
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Table 3.10 Bond angles of the central oxadiazinanone rings in the asymmetric unit of 3. 
 
Atoms-isopropyl Angle (°) Atoms-cyclopentyl Angle (°) 
C6-O1-C2 120.2(1) C56-O51-C52 118.6(1) 
O1-C2-N3 119.0(1) O51-C52-N53 119.1(1) 
O1-C2-O17 117.6(1) O51-C52-O69 117.8(1) 
O17-C2-N3 123.4(2) O69-C52-N53 123.1(2) 
C2-N3-N4 125.8(1) C52-N53-N54 126.8(1) 
N3-N4-C5 107.8(1) N53-N54-C55 108.4(1) 
C14-N4-C5 115.5(1) C64-N54-C55 113.7(1) 
N4-C5-C13 110.2(1) N54-C55-C63 110.7(1) 
C13-C5-C6 113.5(1) C63-C55-C56 113.5(1) 
C5-C6-O1 109.1(1) C55-C56-O51 108.6(1) 
 
 
Table 3.11 Torsion angles of the central rings in the asymmetric unit of 3. 
 
Atoms-isopropyl Torsion (°) Atoms-cyclopentyl Torsion (°) 
C6-O1-C2-N3 1.6(2) C56-O51-C52-N53 7.2(2) 
C6-O1-C2-O17 -177.9(1) C56-O51-C52-O69 -174.6(1) 
C2-O1-C6-C5 29.3(2) C52-O51-C56-C55 -38.4(2) 
C2-O1-C6-C7 155.9(1) C52-O51-C56-C57 -164.9(1) 
O1-C2-N3-N4 -4.1(2) O51-C52-N53-N54 2.4(2) 
O17-C2-N3-N4 175.3(2) O69-C52-N53-N54 -175.7(1) 
C2-N3-N4-C5 -25.9(2) C52-N53-N54-C55 21.7(2) 
C2-N3-N4-C14 101.1(2) C52-N53-N54-C64 -103.1(2) 
N3-N4-C5-C6 55.1(2) N53-N54-C55-C56 -51.6(2) 
N3-N4-C5-C13 -70.0(2) N53-N54-C55-C63 73.7(2) 
C14-N4-C5-C6 -68.9(2) C64-N54-C55-C56 71.0(2) 
C14-N4-C5-C13 166.0(1) C64-N54-C55-C63 -163.7(1) 
N4-C5-C6-O1 -58.2(2) N54-C55-C56-O51 61.2(2)) 
N4-C5-C6-C7 -179.4(1) N54-C55-C56-C57 -176.7(1) 
C13-C5-C6-O1 64.9(2) C63-C55-C56-O51 -62.4(2) 
C13-C5-C6-C7 -56.3(2) C63-C55-C56-C57 59.6(2) 
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Table 3.12 Donor-Acceptor Hydrogen bond lengths in 3. 
 
Donor-
Acceptor Distance, D-A (Å) Bonding Motif 
O17-N53 2.868 Different 
Enantiomorph N3-O69 2.895 
 
 
Crystallographic Details of Quasiracemate of (5R,6S)-4-Cyclopentyl-5-methyl-6-
phenyl-2H-1,3,4-oxadiazinan-2-one and (5S,6R)-4-Cyclohexyl-5-methyl- 
6-phenyl-2H-1,3,4-oxadiazinan-2-one, 4 
 
 Shelxl-201236 was used for refinement. The crystal dimensions are 0.330 mm x 
0.120 mm x 0.100 mm. The temperature was 100K. The unit cell parameters were 
obtained from a least-square refinement of 7852 unique reflections out of the 53541 
reflections collected. The crystal is monoclinic and crystallizes in the P21 space group. 
The cell lengths are: a = 8.8830(3) Å, b = 16.9145(5) Å, and c = 10.0167(3) Å. The 
angles of the cell are α = 90°, β = 106.432(2)°, and γ = 90°. The volume of the cell is 
1443.55(8) Å3 and ρ = 1.230 g/cm3.  Z’ is 2 and Z is 8.  Diffraction data were measured 
between θmin = 2.120° and θmax = 29.290°. . The limiting indices were -12 ≤ h ≤ 12, -23 ≤ 
k ≤ 23, and -13 ≤ l ≤ 13. All hydrogen atoms attached to nitrogen were freely refined and 
all other hydrogen atoms were refined using the riding-model approximation. 
Convergence was reached on the full-matrix least-squares refinement on F2. The R1-
factor is 0.0455 and wR2 is 0.1126.   
ChemDraw30 depictions of the two compounds used to produce 4 are shown in 
Figure 3.7. 
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Figure 3.7  (5S,6R)-4-Cyclohexyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one (left) 
and (5R,6S)-5-methyl-4-cyclopentyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one (right).  
 
 
An ORTEP 33depiction of 4 can be viewed in Figure 3.8. In each figure the 
hydrogen atoms have been omitted for clarity and hydrogen bonds are shown as dotted 
lines. The ellipsoids are modeled at 50% probability.  
 
 
 
Figure 3.8.  Ellipsoid diagram of 4. 
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The bond lengths, bond angles and torsions of the central oxadiazinanone ring are 
shown in Tables 3.13-3.14. The torsions of the oxadiazinanone ring as well as carbons 
attached to the central ring are given in Table 3.11. The hydrogen bond distances and 
angles are displayed in Table 3.15. 
 
Table 3.13 Bond lengths in the central oxadiazinanone ring of 4. 
 
Atoms-Cyclohexyl Bond Length (Å) Atoms-Cyclopentyl Bond Length (Å) 
O1-C2 1.356(3) O51-C52 1.353(3) 
O1-C6 1.442(3) O51-C56 1.446(3) 
C2-N3 1.337(3) C52-N53 1.343(3) 
C2-O20 1.224(4) C52-O69 1.225(4) 
N3-N4 1.422(3) N53-N54 1.429(3) 
N4-C5 1.471(4) N54-C55 1.476(3) 
C5-C6 1.533(3) C55-C56 1.534(3) 
C7-C8 1.391(3) C57-C58 1.393(4) 
 
 
Table 3.14 Bond angles in the central oxadiazinanone rings of 4. 
 
Atoms-
Cyclohexyl Angle (⁰) Atoms-Cyclopentyl Angle (⁰) 
C6-O1-C2 118.6(2) C56-O51-C52 118.9(2) 
O1-C2-N3 119.1(2) O51-C52-N53 118.7(2) 
O1-C2-O20 117.6(2) O51-C52-O69 118.3(2) 
O17-C2-N3 123.3(2) O69-C52-N53 123.0(2) 
C2-N3-N4 126.8(2) C52-N53-N54 126.9(2) 
N3-N4-C5 108.0(2) N53-N54-C55 109.2(2) 
C14-N4-C5 116.1(2) C64-N54-C55 113.9(2) 
N4-C5-C13 110.0(2) N54-C55-C63 110.0(2) 
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Table 3.15 Torsion angles of the central oxadiazinanone rings of 4. 
Atoms-Cyclohexyl Torsion (⁰) Atoms-Cyclopentyl  Torsion (⁰) 
C6-O1-C2-N3 -5.1 (3) C56-O51-C52-N53 7.2(2) 
C6-O1-C2-O20 177.0(2) C56-O51-C52-O69 -174.6(1) 
C2-O1-C6-C5 37.8(3) C52-O51-C56-C55 -38.4(2) 
C2-O1-C6-C7 163.5(2) C52-O51-C56-C57 -164.7(2) 
O1-C2-N3-N4 -5.5(4) O51-C52-N53-N54 4.1(4) 
O20-C2-N3-N4 172.3(2) O69-C52-N53-N54 -173.9(2) 
C2-N3-N4-C5 -19.6(3) C52-N53-N54-C55 18.3(3) 
C2-N3-N4-C14 108.1(3) C52-N53-N54-C64 -107.3(3) 
N3-N4-C5-C6 51.2(2) N53-N54-C55-C56 -48.3(2) 
N3-N4-C5-C13 -74.0(2) N53-N54-C55-C63 76.7(2) 
C14-N4-C5-C6 -73.0(2) C64-N54-C55-C56 75.0(2) 
C14-N4-C5-C13 161.9(2) C64-N54-C55-C63 -160.0(2) 
N4-C5-C6-O1 -61.8(2) N54-C55-C56-O51 59.9(3)) 
N4-C5-C6-C7 177.0(2) N54-C55-C56-C57 -178.7(2) 
C13-C5-C6-O1 61.3(3) C63-C55-C56-O51 -63.0(3) 
C13-C5-C6-C7 -59.9(3) C63-C55-C56-C57 58.4(3) 
 
Table 3.16 Donor-Acceptor Hydrogen bond lengths in 4. 
Donor-
Acceptor Distance, D-A (Å) Bonding Motif 
N3-O69 2.823 Different 
Enantiomorph O20-N53 2.859 
 
 
Crystallographic Details of 5  
 
 In Figure 3.9 is a ChemDraw30 depiction of the product which resulted from the 
attempted synthesis of (5R,6S)-4-ethyl-5-methyl-6-phenyl-3H-1,3,4-oxadiazinan-2-one. 
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Figure 3.9  Line drawing of 5. 
 
 
The dimensions of the crystal used for X-ray diffraction were 0.248 mm x 0.201 
mm x 0.061 mm. The sample was generally kept at 100 K. Superflip37was used for 
solving the structure and Shelxl-201236 was used for refinement.  The unit cell parameters 
were obtained from a least-squares refinement of 5033 unique reflections out of the 
15264 reflections collected. The crystal is orthorhombic and crystallizes in the P212121 
space group. The cell lengths are: a = 7.0046(8) Å, b = 10.0479(11) Å, and c = 20.587(2) 
Å. The volume of the cell is 1448.94 Å3 and ρ = 1.221 g/cm3.  Z’ is 1 and Z is 4. 
Diffraction data were measured between θmin = 1.978° and θmax = 28.271°. The limiting 
indices were -9 ≤ h ≤ 9, -12 ≤ k ≤ 13, and -27 ≤ l ≤ 27. All hydrogen atoms attached to 
nitrogen and oxygen were freely refined and all other hydrogens were refined using the 
riding-model approximation. Convergence was reached on the full-matrix least-squares 
refinement of F2. The R1-factor is 0.0333 and wR2 is 0.0792. Figure 3.10 shows an 
ellipsoid drawing of 5. The ellipsoids are modeled at 50% probability.  
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Figure 3.10  Ellipsoid depiction of 5. 
 
 
The bond lengths, bond angles and torsion angles of the central oxadiazinanone 
ring as well as any carbon atoms attached to the ring are shown in Tables 3.17-19. The 
hydrogen bond lengths are given in Table 3.20.  
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Table 3.17  Bond lengths between atoms in the asymmetric unit of 5. 
 
Atoms Bond Length (Å) 
O1-C2 1.218(2) 
C2-N3 1.350(2) 
C2-O17 1.349(2) 
N3-N4 1.419(2) 
N4-C5 1.490(2) 
N4-C15 1.479(2) 
C5-C6 1.540(2) 
C5-C14 1.529(2) 
C6-C7 1.518(2) 
C6-O13 1.433(2) 
C7-C8 1.391(2) 
C7-C12 1.399(2) 
C8-C9 1.391(3) 
C9-C10 1.385(3) 
C10-C11 1.383(3) 
C11-C12 1.389(3) 
O13-H13 0.82(2) 
C15-C16 1.517(2) 
O17-C18 1.456(2) 
C18-C19 1.505(2) 
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Table 3.18  Bond angles in 5. 
 
Atoms Angle (⁰) 
O1-C2-N3 126.0(2) 
O1-C2-O17 124.9(1) 
N3-C2-O17 109.0(1) 
C2-N3-N4 118.3(1) 
N3-N4-C5 110.1(1) 
N3-N4-C15 108.0(1) 
C5-N4-C15 112.3(1) 
N4-C5-C6 108.4(1) 
N4-C5-C14 109.9(1) 
C6-C5-C14 111.4(1) 
C5-C6-C7 111.5(1) 
C5-C6-O13 110.5(1) 
C7-C6-O13 110.1(1) 
N4-C15-C16 112.1(1) 
C2-O17-C18 116.0(1) 
O17-C18-C19 110.5(1) 
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Table 3.19  Torsion angles in asymmetric unit of 5. 
 
Atoms Torsion (⁰) 
O1-C2-N3-N4 11.3(2) 
O17-C2-N3-N4 -171.2(1) 
O1-C2--O17-C18 -7.6(2) 
N3-C2-O17-C18 174.9(1) 
C2-N3-N4-C5 -115.8(2) 
C2-N3-N4-C15 121.2(2) 
N3-N4-C5-C6 56.6(2) 
N3-N4-C5-C14 178.5(1) 
C15-N4-C5-C6 177.0(1) 
C15-N4-C5-C14 -61.1(2) 
N3-N4-C15-C16 -59.0(2) 
C5-N4-C15-C16 179.4(1) 
N4-C5-C6-C7 179.1(1) 
N4-C5-C6-O13 56.3(2) 
C14-C5-C6-C7 58.0(2) 
C14-C5-C6-O13 -64.7(2) 
C2-O17-C18-C19 -80.1(2) 
 
Table 3.20  Donor-Acceptor Hydrogen bond lengths in 5. 
Donor-Acceptor Distance, D-A (Å) Bonding Motif 
N3-O13 2.941 Homoenantiomorph 
O1-O13 2.893 Intramolecular 
 
 
Crystallographic Details of 6 
 In Figure 3.11 is a ChemDraw30 depiction of the product which resulted from the 
attempted synthesis of (5R,6S)-4-n-propyl-5-methyl-6-phenyl-3H-1,3,4-oxadiazinan-2-
one. 
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Figure 3.11  Line drawing of 6. 
 
 
The dimensions of the crystal used for X-ray diffraction were 0.339 mm x 0.211 
mm x 0.04 mm. The sample was generally kept at 150(2) K. Superflip37 was used for 
solving the structure and Shelxl-201236 was used for structure refinement.  The unit cell 
parameters were obtained from a least-squares refinement of 9971 unique reflections out 
of the 37783 reflections collected. The crystal is monoclinic and crystallizes in the P21 
space group. The cell lengths are: a = 9.6957(2) Å, b = 15.5239(4) Å, and c = 11.5672(3) 
Å. Angle β is 103.4220(10)°. The volume of the cell is 1693.48 Å3 and ρ = 1.155 g/cm3.  
Z’ is 2 and Z is 4. Diffraction data were measured between  θmin = 2.23° and θmax = 
30.26°. The limiting indices were -13 ≤ h ≤ 13, -21 ≤ k ≤ 21, and -15 ≥ l ≤ 15. All 
hydrogen atoms attached to nitrogen and oxygen were freely refined and all other 
hydrogens were refined using the riding-model approximation. Convergence was reached 
on the full-matrix least-squares refinement of F2. The R1-factor is 0.0473 and wR2 is 
0.1274  Figure 3.12 shows an ellipsoid drawing of 6. The ellipsoids are modeled at 50% 
probability.  
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Figure 3.12  Ellipsoid depiction of 6. 
 
 
The bond lengths, bond angles and torsion angles of the central oxadiazinanone 
ring as well as any carbon atoms attached to the ring are shown in Tables 3.21-24. The 
hydrogen bond lengths are shown in Table 3.24.  
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Table 3.21  Bond lengths between atoms in the asymmetric unit of 6. 
 
Atoms-Molecule 1 Length (Å) Atoms-Molecule 2 Length (Å) 
O1-C2 1.217(3) O51-C52 1.215(3) 
C2-N3 1.343(3) C52-N53 1.335(3) 
C2-O19 1.337(3) C52-O69 1.342(3) 
N3-N4 1.404(3) N53-N54 1.418(3) 
N4-C5 1.484(3) N54-C55 1.491(3) 
N4-C15 1.468(3) N54-C65 1.477(3) 
C5-C6 1.549(3) C55-C56 1.540(3) 
C5-C14 1.517(3) C55-C64 1.529(4) 
C6-C7 1.518(3) C56-C57 1.510(3) 
C6-O13 1.423(3) C56-O63 1.423(2) 
C15-C16 1.530(4) C65-C66 1.521(3) 
C16-C17 1.513(4) C66-C67 1.519(4) 
C17-18 1.471(6) C67-C68 1.514(4) 
O19-C20 1.442(4) O69-C70 1.457(5) 
C20-C21 1.485(4) C70-C71 1.477(8) 
 
 
Table 3.22  Bond angles in 6. 
 
Atoms-Molecule 1 Angle (°) Atoms-Molecule 2 Angle (°) 
O1-C2-N3 126.1(2) O51-C52-N53 125.5(2) 
O1-C2-O19 124.8(2) O51-C52-O69 123.7(2) 
N3-C2-O19 109.1(2) N53-C52-O69 110.7(2) 
C2-N3-N4 120.3(2) C52-N53-N54 117.6(2) 
N3-N4-C5 112.6(2) N53-N54-C55 110.4(2) 
N3-N4-C15 109.2(2) N53-N54-C65 108.0(2) 
C5-N4-C15 113.9(2) C55-N54-C65 114.8(2) 
N4-C5-C6 114.5(2) N54-C55-C56 108.2(2) 
N4-C5-C14 109.7(2) N54-C55-C64 110.1(2) 
C6-C5-C14 112.1(2) C56-C55-C64 110.3(2) 
C5-C6-C7 111.4(2) C55-C56-C57 111.4(2) 
C5-C6-O13 108.1(2) C55-C56-O63 111.6(2) 
C7-C6-O13 112.6(2) C57-C56-O63 110.1(2) 
N4-C15-C16 110.3(2) N54-C65-C66 111.6(2) 
C15-C16-C17 113.3(2) C65-C66-C67 112.4(2) 
C16-C17-C18 114.2(4) C66-C67-C68 112.3(3) 
C2-O19-C20 115.9(2) C52-O69-C70 115.4(3) 
O19-C20-C21 107.1(3) O69-C70-C71 109.0(4) 
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Table 3.23  Torsion angles in asymmetric unit of 6 
 
Atoms-Molecule 1 Torsion (°) Atoms-Molecule 2 Torsion (°) 
O1-C2-N3-N4 1.2(4) O51-C52-N53-N54 9.2(3) 
O19-C2-N3-N4 -178.6(2) O69-C52-N53-N54 -171.6(2) 
O1-C2-O19-C20 0.3(3) O51-C52-O69-C70 1.7(4) 
N3-C2-O19-C20 -179.9(2) N53-C52-O69-C70 -177.6(3) 
C2-N3-N4-C5 -113.7(2) C52-N53-N54-C55 -115.4(2) 
C2-N3-N4-C15 118.7(2) C52-N53-N54-C65 118.4(2) 
N3-N4-C5-C6 -60.3(2) N53-N54-C55-C56 60.5(2) 
N3-N4-C5-C14 66.8(2) N53-N54-C55-C64 -178.9(2) 
C15-N4-C5-C6 64.8(2) C65-N54-C55-C56 -177.2(2) 
 -168.1(2) C65-N54-C55-C64 -56.5(2) 
N3-N4-C15-C16 -72.3(2) N53-N54-C65-C66 -68.9(2) 
C5-N4-C15-C16 160.9(2) C55-N54-C65-C66 167.5(2) 
N4-C5-C6-C7 -162.4(2) N54-C55-C56-C57 -173.7(2) 
N4-C5-C6-O13 73.4(2) N54-C55-C56-O63 62.7(2) 
C14-C5-C6-C7 71.8(2) C64-C55-C56-C57 65.8(2) 
C14-C5-C6-O13 -52.4(2) C64-C55-C56-O63 -57.7(2) 
C5-C6-C7-C8 -95.5(3) C55-C56-C57-C58 69.6(3) 
C5-C6-C7-C12 85.2(3) C55-C56-C57-C62 -111.3(2) 
O13-C6-C7-C8 26.1(3) O63-C56-C57-C58 -166.0(2) 
O13-C6-C7-C12 -153.2(2) O63-C56-C57-C62 13.1(3) 
N4-C15-C16-C17 171.8(2) N54-C65-C66-C67 175.4(2) 
C15-C16-C17-C18 64.8(4) C65-C66-C67-C68 172.3(3) 
C2-O19-C20-C21 -179.0(2) C52-O69-C70-C71 -159.2(3) 
 
 
Table 3.24  Donor-Acceptor Hydrogen bond lengths in 6. 
Donor-Acceptor Distance, D-A (Å) Bonding Motif 
O13-N3 2.883 Intramolecular 
O13-O51 2.908 Heteroenantiomorph 
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Summary of Crystallographic Details of Crystals Studied in This Research                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
Tables 3.25 and 3.26 summarize the crystallographic details in this research. 
 
Table 3.25 Summary data for crystallographic details of the oxadiazinanone crystals in 
this thesis. 
 
Compound 1 2 3 4 
N4 Substituent/type cyp/pure (5R,6S) 
cyp 
/racemic 
(5S,6R)cyp/ 
(5R,6S)iso 
(5S,6R(cyp)/ 
(5R,6S)iso 
Formula C15H2-N2O2 C15H20N2O2 C28H38N4O4 C31H42N4O4 
Crystal Setting orthorhombic monoclinic monoclinic Monoclinic 
Space Group P212121 P21/c P21 P21 
Crystal Size    
(mm3) 
0.360 x 0.270 x 
0.210 
0.195 x 0.138 x 
0.137 
0.449 x 0.211 x 
0.102 
0.330 x 0.120 x 
0.100 
a (Å) 8.4171(3) 9.1808(3) 10.4323(3) 8.8830(3) 
b (Å) 9.0618(4) 15.7560(5) 8.7068(2) 16.915(5) 
c (Å) 36.7815(13) 9.7293(3) 14.6212(4) 10.0167(3) 
α (°) 90 90 90 90 
β (°) 90 106.132(2) 94.1200(10) 106.432(2) 
γ (°) 90 90 90 90 
V Å3 2805.47 1351.95 1324.64 1443.55(8) 
Z; Z' 2; 8 1;4 1;2 2;8 
Density 1.233 1.279 1.240 1.230 
Temperature 80(2) K 293(2) K 293(2) K 100(2) K 
Total # reflections 17571 19297 52929 53541 
R1-factor 0.0432 0.0381 0.0427 0.0455 
ωR2  0.1029 0.0926 0.1098 0.1126 
Unique reflections 4581 2460 8339 7852 
S 1.160 1.034 1.036 1.019 
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Table 3.26  Summary of crystallographic details of crystals studied in this research which 
were not oxadiazinanones. 
 
Compound 5 6 
Formula C14H22N2O3 C16H26N2O3 
Crystal Setting orthorhombic monoclinic 
Space Group P212121 P21 
Crystal Size (mm3) 0.248 x 0.201 x 0.061 0.339 x 0.211 x 0.04 
a (Å) 7.0046(8) 9.6957(2) 
b (Å) 10.0479(11) 15.5239(4) 
c (Å) 20.587(2) 11.5672(3) 
α (°) 90 90 
β (°) 90 103.4220(10) 
γ (°) 90 90 
V Å3 1448.94 1693.48 
Z; Z' 1;4 2;4 
density g/cm3 1.221 1.155 
Temperature 100(2) K 150(2) K 
Total # reflections 15264 37783 
R1-factor 0.0333 0.0473 
ωR2  0.0792 0.1274 
Unique reflections 5033 9971 
S 1.038 1.02 
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CHAPTER IV 
DISCUSSION OF CRYSTAL STRUCTURES 
 In order to better understand the similarities and differences in the oxadiazinanone 
compounds studied during this research, it would be helpful to have a summary of some 
of the relevant crystallographic details.24, 26, 38 The crystal packing and hydrogen-bonding 
motifs will be compared and contrasted in an attempt to understand what causes some 
oxadiazinanones to fail to fractionally crystallize and others to succeed.  In addition, each 
of the new crystal structures found during this research will be discussed. 
Summary of the Formation of Quasiracemic Crystals and Some Key 
Crystallographic Data Pertaining to the Oxadiazinanones Studied 
 
 Tables 4.1-4 summarize the information for each of the enantiomers studied. 
Table 4.1 gives the results for each attempt made to isolate a quasiracemic crystal. If a 
quasiracemic crystal formed (failure of fractional crystallization), the term “quasi,” 
highlighted in blue, can be seen. If a combination was not attempted, the designation N/A 
is given. When enantiomers of an oxadiazinanone form a racemic crystal, it is highlighted 
in peach. In cases of fractional crystallization, the data show which quasienantiomer was 
found (based on the N4 substituent). Tables 4.2-4.3 give crystallographic details for pure 
structures, racemic structures and quasiracemic structures of oxadiazinanones, 
respectively. In Tables 4.2-4.4 the hydrogen-bonding motif refers to whether the 
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hydrogen bonds occur between structures with the same chirality (enantiomorphs) or the 
opposite chirality. The bonds between molecules with the same chirality are called homo 
enantiomorphic bonds. The bonds between molecules with different chirality are called 
hetero enantiomorphic bonds. 
 
Table 4.1 Fractional crystallization results of the combination of (5R,6S)oxadiazinanones 
and (5S,6R) oxadiazinanones.  
 
  
N4 Substituent on (5R,6S) Oxadiazinanone 
N4 
Substituent 
on (5S,6R) 
Oxadiazina-
none 
 cyclohexyl 
cyclo-
pentyl isopropyl n-propyl methyl 
cyclohexyl racemate2 quasi quasi2 cyclohexyl methyl 
cyclopentyl quasi racemate quasi cyclopentyl methyl 
isopropyl quasi2 N/A3 racemate1 isopropyl methyl 
n-propyl N/A3 N/A3 N/A3 racemate1 N/A3 
methyl methyl N/A3 N/A3 N/A3 racemate1 
1Racemates are assumed to form. However the cyclopentyl racemate was the only 
racemate attempted in this research. 
2 Kate Edler crystallized and reported on these crystals.26  
3N/A indicates the combination was not attempted or crystals were not obtained. 
 
Table 4.2 Crystallographic details of enantiomerically pure compounds. 
  N4 
substituent 
Space 
Group 
Crystal 
Setting Z; Z' 
 No. of H-Bonds; Motif 
(Asymmetric Unit) 
cyclohexyl (7) P212121 orthorhombic 16; 4 4; homo-enantiomorph 
cyclopentyl (1)   P212121 orthorhombic 8; 2 2; homo-enantiomorph 
isopropyl (9) P212121 orthorhombic 8; 2 2; homo-enantiomorph 
n-propyl (13) P21 monoclinic 4; 2 4; homo-enantiomorph 
methyl (12) P21 monoclinic 2; 1 2; homo-enantiomorph 
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Table 4.3 Crystallographic details of racemic compounds. 
N4 substituent 
Space 
Group 
Crystal 
Setting Z; Z’ 
No. of H-Bonds; Motif 
(Asymmetric Unit) 
isopropyl (11) C2/c monoclinic 8; 1 2; hetero-enantiomorph 
cyclopentyl (2) P21/c monoclinic 4; 1 2; hetero-enantiomorph 
cyclohexyl(10) P-1 triclinic 4; 2 4; hetero-enantiomorph 
 
 
Table 4.4 Crystallographic details of quasiracemic compounds. 
N4 substituents 
Space 
Group 
Crystal 
Setting Z; Z’ 
No. of H-Bonds; Motif 
(Asymmetric Unit) 
isopropyl/cyclopentyl (3)  P21 monoclinic 4; 2 4; hetero-enantiomorph 
isopropyl/cyclohexyl (8) P21 monoclinic 4; 2 4; hetero-enantiomorph 
cyclohexyl/cyclopentyl (4) P21 monoclinic 4; 2 4; hetero-enantiomorph 
 
 
Most of the oxadiazinanones studied have Z’ > 1. Compound 7 has Z’ of 4. Table 
4.5 shows that of the more than 600,000 structures in the Cambridge Structural Database 
a Z’ ≤ 1 occurs in about 88% of the crystals. A Z’ of 2 is much less common, and Z’  of  4 
is encountered less than 0.4 % of the time.39  These unusually high Z’ values may provide 
insight into why some of the compounds form quasiracemic crystals and others do not.  
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Table 4.5 The occurrence frequency of structures between Z’ ranges in the Cambridge 
Structural Database in 2013.39 
 
 
 
 
 
 
 
 
 
 
 
In each quasiracemic crystal the Z’ is less than or equal to the Z’ of the component 
quasienantiomers. This is especially notable in the cyclopentyl/cyclohexyl quasiracemate. 
The cyclopentyl quasienantiomer, 1, has a Z’ of 2, and the cyclohexyl quasienantiomer, 7, 
has a Z’ of 4. After mixing the quasienantiomers together and crystallizing them, the 
resulting quasiracemate, 3, has a Z’ of 2. Since this Z’ of 2 includes the two 
quasienantiomers, it would be comparable to a Z’ of 1 in a racemate crystal. When the 
methyl quasienantiomer is combined with any other quasienantiomer, the methyl always 
fractionally crystallizes.  
Kitaigorodskii’s close-packing principle states that reduction of volume and 
increase in density are major factors in determining the ease with which molecules pack 
in the solid state.40 Brock and Dunitz noted that structures with large Z’ values are 
associated with packing conflicts. Packing conflicts make it difficult to crystallize some 
compounds.34 Although Z’ for 7 is 4, when it co-crystallizes with 1 or 9 the resulting 
quasiracemic crystal has Z’ of 2 which is comparable to a Z’ of 1 in a racemate. This may 
indicate reduction in packing conflict with the quasiracemate crystal as compared to that 
Range of Z’ % Structures 
0 ≤ Z’ ≤ 1 88.2% 
1 < Z’ ≤ 2 10.5% 
2 < Z’ ≤ 3 0.6% 
3 < Z’ ≤ 4 0.4% 
4 < Z’ 0.1% 
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of either of the pure oxadiazinanone enantiomers making up the racemates.  
According to Braun et al., Z’ of 1 is commonly found in racemic crystals, and he 
indicated that inversion symmetry is a probable reason.41 In a study by Kelley et al. it was 
found that inversion symmetry is very favorable for crystal packing. Inversion symmetry 
generally allows the molecules in the crystal to pack in less space, a factor which favors 
crystallization according to the close-packing principle.1 Brook et al. observed that the 
majority of crystallizations from racemic solutions lead to racemic crystals.42 The most 
common space groups, P1, P21/c, C2/c and Pbca, are racemic and these four space 
groups account for approximately two-thirds of all organic crystals.42 Even though 
quasiracemates do not form true inversion centers, there are pseudo-inversion centers. 
The presence of these pseudo-inversion centers may make the quasiracemic crystal more 
stable than either of the quasienantiomeric crystals. This would explain why 3, 4, and 8 
form quasiracemic crystals.  It seems the value of Z’ of the constituents has some impact 
on Z’ of the quasiracemic crystal. The pseudo-inversion possible with quasiracemic 
crystals also seems to reduce packing conflicts. If packing conflicts can be alleviated by 
the formation of a quasiracemic crystal, the quasiracemic crystal is more likely to 
crystallize than either of the oxadiazinanone quasienantiomers.  
Another observation can be made from the data in Table 4.1. When the isopropyl 
derivative and the n-propyl derivative were mixed, the isopropyl derivative crystallized. 
When the cyclohexyl and methyl derivatives were mixed, the methyl derivative 
crystallized. Finally, when the cyclohexyl and the n-propyl derivatives were mixed, the 
cyclohexyl was crystallized. The n-propyl group is more flexible than the isopropyl group 
which may help to make it more soluble in the ethyl acetate used for the crystallization 
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process. In Figure 4.1, the connecting motif from N4 to the carbon on the N4 substituent 
is highlighted in blue. The cyclohexyl and cyclopentyl substituents have a connection 
with N4 similar to that of isopropyl, and they crystallize more readily than the 
oxadiazinanone with the n-propyl substituent which indicates that they may be more 
stable and able to crystallize more easily. In combinations which included a 
quasienantiomer with methyl as the N4 substituent, the quasienantiomer with an N4 of 
methyl always crystallized first. Methyl is the smallest N4 substituent and will have the 
least flexibility possible.  
 
N
CH3
O NH
O
N
CH3
O NH
O
N
CH3
O NH
O
 
Figure 4.1 Line drawings of 9, 10, and 12. 
 
 
The principle that says crystallization favors the reduction of packing conflicts 
can be observed in the results of the crystallization studies shown in Tables 4.1-4.4. 
There seems to be indications that flexibility in a compound’s bonds impacts 
crystallization. When 13, the n-propyl derivative, was mixed with a quasienantiomer, 13 
appeared to remain in solution. Each time 12, the methyl derivative was mixed with a 
quasienantiomer, 12 was the crystal which was isolated. From this it seems that when 
methyl is the N4 substituent, it can be crystallized with few packing conflicts. On the 
other hand, when n-propyl is the N4 substituent it is less likely to crystallize. This could 
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be due to the flexibility in its structure which can create packing conflicts.  
It is always important to note that only one crystal from each product was 
analyzed by X-ray diffraction. If one determines the existence of a quasiracemic crystal, 
the certainty is that the combination of quasienantiomers can form a quasiracemate. In the 
case of no quasiracemic crystal being found, one can only say for certain that a 
quasiracemate was not found. 
Hydrogen bonding remains a significant driving force in the determination of the 
shapes of crystal.40 The most acidic hydrogen atoms will bond with the most readily 
available hydrogen acceptors. In the case of the oxadiazinanones, the hydrogen bonding 
always has the form, R22(8).14 This means the hydrogen bonds form an eight-member ring 
with two hydrogen bond donors and two acceptors. The hydrogen bond occurs between 
the carbonyl groups and the amine hydrogens on the molecules in the crystal. According 
to the literature,38 the bond lengths between the C3-N3 carbons in oxadiazinanones which 
are unsubstituted at the N3 position (the case for all the oxadiazinanones studied in this 
research) is shorter than those which are substituted.  The C3-N3 bond lengths in 
oxadiazinanones unsubstituted at N3 are in the range 1.389-1.418Å. Two structures 
substituted at N3 have C3-N3 bond lengths of 1.337(2) Å and 1.342(2) Å.39 This 
indicates the presence of greater double bond character for this bond.  This double bond 
character could play a role in the strong preference these compounds have for hydrogen-
bonding. It is worth noting that hydrogen bonding can occur between the same 
enantiomorphs, referred to as a homo-enantiomorph motif, or different ones, a hetero-
enantiomorph motif. Tables 4.2-4.4 indicate the bonding motif for each crystal studied. 
Another driving force for a particular type of crystal packing is the minimization 
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of electrostatic energy. Although this is very important in ionic crystals, it also is true in 
molecular crystals.40 The localized charges on the atoms are small, but remain important 
in the packing of the crystals. Minimizing these forces happens when positive and 
negative charges are optimized. As described by Brock, this is much like having bumps 
against hollows, donors against acceptors, positive ends of dipoles against negative 
ends.40 This helps to increase density and minimize volume, implying reduced packing 
conflicts. Hydrogen-bonding which is prevalent in oxadiazinanone crystals can help to 
minimize electrostatic energy. 
            Springuel et al. summarized the formation of co-crystals by concluding that the 
formation of co-crystals is a summation of molecular geometry, steric hindrance and 
hydrogen-bonding.43 This appears to be the case in the structures of this thesis. 
Analysis of (5R,6S)-4-Cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one, 1 
Compound 1 packs in space group P212121.  This non-centrosymmetric group has 
three screw axes orthogonal to each other with no other symmetry elements. Because 
there is no other symmetry, the two molecules are not crystallographically identical. This 
could be due to conformational differences in the two molecules or flexibility in the 
hydrogen-bonding.44 There are two molecules in the asymmetric unit. The packing 
diagram is shown in Figure 4.2.  
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Figure 4.2 Packing diagram of 1. 
 
 
 The data from an X-ray diffractometer must be converted to a set of coordinates 
which describe the crystal in three-dimensional space. Once this data has been obtained, 
Mercury a software package developed by the Cambridge Crystallographic Data Centre, 
can create images of the crystals. This data can be used  to analyze crystal structures 
including bond distances, torsion angles, hydrogen bonding and symmetry. One reason 
for having more than one molecule in the asymmetric unit of a crystal is that the 
molecules have different conformations.41 To determine whether this is the case for 1, an 
overlay was done using Mercury.45 In Figure 4.3 is a wireframe depiction of 1. The three 
atoms in the central oxadiazinanone ring marked in yellow were chosen as the atoms over 
which a least squares fit was calculated.  
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Figure 4.3   Overlay of the two molecules in the asymmetric unit of 1. 
 
 When an overlay is calculated in Mercury,45 the closest fit will be found in the 
atoms chosen for the least squares calculation, and the farther from these atoms one goes, 
the greater the differences will appear. Figure 4.3 shows that these two molecules differ 
the most in their structure where the cyclopentyl group is located. This could be the 
source of the unexpected asymmetry.  Even when the overlay is calculated using atoms in 
the cyclopentyl substituent, there is still a difference in the conformation of the 
cyclopentyl group. 
  When two molecules are present in the asymmetric unit of pure enantiomers, 
hydrogen bonding can allow some flexing of the bonds. This creates some slight 
differences in the two molecules. This flexing creates a situation which distorts the 
inversion centers.1 
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Analysis of the Racemate of 4-Cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-
2-one, 2 
 
 Compound 2 crystallizes in the non-chiral, centrosymmetric space group P21/c, 
the most common space group. This space group comprises over one-third of the crystals 
in the Cambridge Structural Database.46 Because the crystal is a racemate it does not have 
optical activity.  Although two different enantiomers are present in the structure, there is 
only one molecule in the asymmetric unit (Z’ = 1) because the enantiomers, by definition, 
are mirror images of each other. That means that if there is one enantiomer present, the 
other can be obtained by a symmetry operation (inversion). The unit cell has two glide 
planes, two 2-fold screw axes and an inversion center.  The packing diagram in Figure 
4.4 shows the 4 structures in the unit cell.  
 
 
 
Figure 4.4  Packing diagram of 2.  
 
 
In the racemate, 2, hydrogen-bonding is observed between different 
enantiomorphs in the crystal. This differs from the bonding that occurs in 11 (see Table 
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4.3) where the hydrogen bonding occurs between the same enantiomorphs even though it 
is also a racemic crystal. 
Analysis of the Quasiracemate of (5R,6S)-5-Methyl-4-cyclopentyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one and (5S,6R)-4-Isopropyl-5-methyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one, 3 
 
 Compound 3 packs in the non-centrosymmetric space group P21 and has one 
symmetry element, a screw axis. The hydrogen-bonding motif is hetero-enantiomorphic. 
There are 2 molecules in the asymmetric unit (see Figures 3.9 and 10). The packing 
diagram can be seen in Figure 4.5. 
 
 
 
Figure 4.5  Packing diagram of 3.  
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 This quasiracemate compares to 8 (see Table 4.4) in that they both crystallize in 
the space group P21. Both have two molecules in the asymmetric unit—one 
oxadiazinanone with an N4 cyclohexyl substituent and the other with an N4 substituent of 
isopropyl or cyclopentyl. This compound could possibly be modeled as a 
centrosymmetric crystal with disorder in the area of the isopropyl and cyclopentyl 
substituents with half occupancy of each of the substituents. Figure 4.6 shows an overlay 
of the quasienantiomers. The hydrogen atoms have been omitted for clarity. 
 
Figure 4.6  Overlay of 2 and 3. 
 
 
 In this overlay the nitrogen atoms and oxygen atoms used in the hydrogen-
bonding have been used to determine the least squares alignment of the structures. It is 
important to note that as one looks further from the center where the structures are 
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aligned, the differences become more exaggerated. In this overlay it seems that the 
isopropyl substituent and the cyclopentyl constituent are closely aligned and that this 
could be solved in a centrosymmetric space group. 
In Figure 4.7 one can compare the hydrogen-bonded dimers of 2 and 3. The 
similarities are striking—again making a case for the possibility of solving the structure 
in a centrosymmetric space group. The hydrogen atoms have been omitted for clarity. 
 
 
 
Figure 4.7  The hydrogen-bonded dimers of 2 (top) and 3 (bottom).  
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 Compound 2 has an inversion center located within the hydrogen bonds and, of 
course 3, does not. However, Compound 3 could have a pseudo-inversion center located 
within the hydrogen bonds.  Figure 4.8 shows 2 and 3 from an angle which allows one to 
compare the hydrogen bonds. Again, hydrogen atoms have been omitted for clarity. 
 
 
Figure 4.8  The upper structure is a wireframe depiction of  the quasiracemate, 3, and the 
lower structure is that of the racemate, 1. Both structures are shown from a perspective 
parallel to the hydrogen-bonds.   
 
 
 In Figure 4.8 one can see that the hydrogen bonds in 1 appear parallel to each 
other and the molecule does not show much flexion in the bonds. In 3, the hydrogen 
bonds are skewed in slightly different directions, and there is some flexing of the 
different enantiomers. This is further evidenced in the difference in the torsion angles 
between the four atoms which are hydrogen bonded. In 1 the torsion angle is 0.00(5)° and 
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in 3 the torsion angle is 3.86(6)°. The distances between the nitrogen and oxygen atoms 
in the hydrogen bonds in 3 are 2.868(2) Å and 2.895(2) Å. The distance between the 
nitrogen and oxygen atoms in the hydrogen bonds in 2 is 2.824(2) Å. It can be seen, 
therefore, that there is more discrepancy between the structures than is immediately 
evident.  
Analysis of the Quasiracemate of (5R,6S)-5-Methyl-4-cyclopentyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one and (5S,6R)-4-Cylohexyl-5-methyl-6-phenyl-2H-1,3,4-
oxadiazinan-2-one, 4 
 
 Compound 4 crystallizes in the monoclinic, chiral P21 space group. There are two 
molecules in the asymmetric unit (see Figure 3.11). The only symmetry element present 
is a two-fold screw axis.  As in 2, hydrogen bonding in 4 occurs between the two 
quasienantiomers in a hetero-enantiomorph motif. In Figure 4.9 one can see the packing 
of 4 in the unit cell. Hydrogen atoms have been omitted for clarity. 
 
 
Figure 4.9  Packing diagram of the unit cell of 4.  
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In Figure 4.10 one can see the overlay of 2 (racemate) and 4 (quasiracemate). In 
this overlay the nitrogen atoms and oxygen atoms at each of the double bonds have been 
used in the least squares analysis. These atoms near the center of the structure are forced 
to be aligned as closely as possible which cause the differences to be exaggerated as one 
analyzes the differences further from the center. With that concept in mind, one can see 
the close alignment of the cyclopentyl group in the racemate and the cyclohexyl group in 
the quasiracemate.   
 
 
 
Figure 4.10  Overlay of 2 and 4.  
 
 
In Figure 4.11 one can see that the hydrogen bonds in 2 and 4 are very similar and 4 
seems to have little flexion. In 1 the torsion angle is 0.00(5)° and in 3 the torsion angle is 
0.52(9)°.  The distances between the nitrogen and oxygen atoms in 4 are 2.859(3) Å and 
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2.823(3) Å. The distance between the nitrogen and oxygen atoms in each of the hydrogen 
bonds in the racemate 2 is 8.824(2) Å. 
 
 
 
 
Figure 4.11  Hydrogen-bond comparison of 2 (top) and 4 (bottom).  
 
  The comparison of the hydrogen bond angles and torsion angles between 2 and 4 
are closer than those between 2 and 3 as can be seen in Table 4.6. 
 
Table 4.6  Torsion angles and bond distances in the hydrogen bond motifs of 2, 3 and 4.  
 
 Hydrogen Bond Distances (Å) Donor to Acceptor Atoms Torsion Angles (°) 
Compound 2 2.824(2) Å N3-O19-N3-19 0.00(5) 
Compound 3 2.868(2) Å;  2.895(2) Å O69-N3-O17-N53 3.86(6) 
Compound 4 2.859(3) Å; 2.823(3) Å O69-N5-O20-N53 0.52(9) 
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 The similarity in the structure for racemic cyp and cyp/cyh leads one to wonder if 
the quasiracemate could be solved in a centrosymmetric space group modeling a disorder 
with the cyclohexyl quasiracemate and the cyclopentyl racemate present in equal 
amounts. This modelling was attempted and Figure 4.12 shows the resulting asymmetric 
unit. 
 
Figure 4.12  Asymmetric unit of 4 solved in P21/c space group. 
 
 
In this structure the lengths of the hydrogen bonds are both 2.77(1) Å. The torsion 
angles are 0.0°. These values are constrained because the second molecule is generated 
by an inversion.  The extra atoms that can be seen around the N4 substituent represent the 
disorder at the N4 substituent.  When solved in the centrosymmetric space group P21/c, Z 
= 4 and Z’ = 1. The R1-factor is 0.1635 and wR2 is 0.3397. The R-factors are higher than 
what should be accepted in a structure, but it is conceivable that they are low enough that 
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this could be used as a proof of concept. The definition of a quasiracemate could be 
changed to reflect the ability of the structure to be solved in a centrosymmetric space 
group with some higher level of R-values, weighted or un-weighted. This definition does 
not mean the structure should be solved and published as a centrosymmetric crystal, but 
that the structure is capable of being solved in a centrosymmetric space group. This also 
indicates that the Z‘ = 2 of 4 is a bit misleading, because it is much like 2 which has a Z’ 
of 1. 
Analysis of 5 
Compound 5 (Figure 3.13) was the result of an attempt to synthesize an 
oxadiazinanone substituted at the N4 position with an ethyl group. The cyclization 
reaction, after purification with flash chromatography, appeared to produce the desired 
product based on the 1H NMR spectrum. 
After solving the structure using X-ray diffraction, it was found that the N4 
substituent was the ethyl group but the ring had not closed. It is possible that the desired 
product was produced in addition to the product which was identified by X-ray 
diffraction, but the oxadiazinanone was more soluble than the non-cyclized product and 
did not crystallize. Figure 4.13 gives the reaction for the synthesis of the non-cyclized 
product, (1S,2R) 2-[N-ethyl-N’-o-ethyl hydrazinoate]-1-phenyl-propan-2-ol, 5, from the 
hydrazine of the ethyl derivative of  (1S,2R) norephedrine.  
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Figure 4.13  An attempt to cyclize the hydrazine of the ethyl derivative of (1S,2R) 
norephedrine resulted in 5. 
 
 
 Compound 5 crystallizes in the orthorhombic space group, P212121, and has one 
molecule in the asymmetric unit (Z’ = 1). The compound has three 2-fold screw axes as 
the only elements of symmetry. The asymmetric unit has two hydrogen bonds. Figure 
3.14 shows that one of the hydrogen bonds is homoenantiomophic and one is an 
intramolecular bond. It is interesting to note that the hydroxyl group at O13 is a proton 
donor to the intramolecular carbonyl group and a proton acceptor from the secondary 
amine at N3. In Figure 4.14, it can be seen that there are four molecules in the unit cell, 
therefore Z = 4.  
 
Figure 4.14  Packing diagram of the unit cell of 5.  
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Analysis of 6 
 Compound 6 (Figure 3.14) was the result of an attempt to synthesize an 
oxadiazinanone substituted at the N4 position with an n-butyl group. The cyclization 
reaction, after purification with flash chromatography, appeared to produce the desired 
product based on the 1H NMR spectrum.  
After solving the structure using X-ray diffraction, it was found that the N4 
substituent was the n-butyl group but the ring had not closed. It could be that the desired 
product was produced in addition to the product which was identified by X-ray 
diffraction, but the oxadiazinanone was more soluble than the non-cyclized product and 
did not crystallize. Figure 4.15 gives the reaction for the synthesis of the non-cyclized 
product, (1S,2R) 2-[N-n-butyl-N’-o-n-butyl hydrazinoate]-1-phenyl-propan-2-ol, 6, from 
the hydrazine of the n-butyl derivative of (1S,2R) norephedrine. 
. 
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Figure 4.15  An attempt to cyclize the hydrazine of the n-butyl derivative of (1S,2R) 
norephedrine resulted in synthesis of 6. 
 
 
 The compound crystallizes in the monoclinic space group, P21, and has two 
molecules in the asymmetric unit (Z’ = 2). The only symmetry element is a two-fold 
screw axis. This compound has only two hydrogen bonds. One of the bonds is 
intramolecular. The other is between a carbonyl group and an alcohol group on the other 
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molecule in the asymmetric unit. Using symbols and terminology of Etter et al.,14 this 
would have two motifs, S(6) and D, indicating the intramolecular bond (S) and the bond 
between the two molecules of the asymmetric unit (D).   
 Figure 4.16 shows the packing diagram of the unit cell. The two molecules, 
although the same compound, have different conformations. This is readily apparent 
when the two molecules are compared in Tables 3.22 and 3.23. The n-butyl group has 
enough flexion in the bonds and angles that perhaps the conformation changes enable the 
molecules to pack more densely.  
  
Figure 4.16  Packing diagram of the unit cell of 6.  
 
 
 Polymorphic transformation was displayed in 6. When the temperature of data 
collection of the n-butyl derivative was 150 K, the crystal was monoclinic and when the 
temperature was lowered to 100 K, the crystal morphed to a triclinic crystal. 
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Crystallographic details could not be determined as the crystal shattered as it was cooled 
down. Polymorphic transformation can occur as the sizes of the atoms making up the 
compound increase or decrease based on the temperature. As the vibrations in the atom 
increase with increasing temperature, the increasing size of the molecule may make a less 
compact crystal more stable.47 The incidence of polymorphism is common if this 
statement of Walter C. McCrone is true:  “Every compound has different polymorphic 
forms, and that, in general, the number of forms known for a given compound is 
proportional to the time and money spent in research on that compound.”48,49   
 In each of 5 and 6, the diethyl carbonate attached as expected to the amine group, 
but failed to attach at the hydroxyl group.  The hydroxyl group has a stronger bond than 
the ammonia group, so the ammonia group left first and allowed the attachment of the 
diethyl carbonate. Changing the experimental procedure could produce the desired 
oxadiazinanone in each case.  If the hexanes used as the solvent are not completely dry, 
the LiH will react with water more readily than with the hydrazine. Therefore, every 
effort must be made to ensure that the hexanes are dry. If the fourth step of the synthesis 
is repeated with the uncyclized product, the desired oxadiazinanone should be obtained. 
The LiH:hydrazine mole ratio was 1:2. Perhaps a greater concentration of LiH would also 
be effective in producing the oxadiazinanone. 
General Conclusions and Future Work 
 At this point in the study of quasiracemates, the need is to acquire a database of 
structures. From this database it is hoped that the reasons for the formation of 
quasiracemic crystals with some compounds and not others can be elucidated. The 
knowledge gained from the study has the potential to direct the engineering of crystals to 
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meet specific needs. To that end, this research can be helpful. The more data collected, 
the more knowledge may be gained about the reasons for quasiracemate co-
crystallization. 
 The research goals for this project were met. The inventory of oxadiazinanones 
was increased. A new oxadiazinanone, (5R,6S)-4-cyclopentyl-5-methyl-6-phenyl-2H-
1,3,4-oxadiazinan-2-one, was synthesized.  Attempts to combine oxadiazinanone 
enantiomers to form quasiracemates were made and two new quasiracemates were 
formed. Hydrogen bonding and the number of structures in the asymmetric unit were 
investigated as they related to the formation of the quasiracemates. The structure 
similarities of those quasienantiomers involved in quasiracemate formation were 
compared and an isopropyl type of connection to N4 seemed to be a common bond.  
  How similar must the quasienantiomers be to co-crystallize? Further research 
with oxadiazinanones with different N4 substituents would be useful in determining this. 
Will oxadiazinanones form quasiracemates with oxadiazinathiones?  Will the 
crystallization of oxadiazinathiones quasiracemates mirror that of oxadiazinanone 
compounds? The synthesis of oxadiazinanthiones with varying N4substiuents and the 
subsequent combination of them with other oxadiazinanthiones or oxadiazinanones will 
provide new data. This data will perhaps provide new answers and probably raise some 
more questions.  
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